Potent	O
and	O
stable	O
attenuation	O
of	O
live-HIV-1	O
by	O
gain	O
of	O
a	O
proteolysis-resistant	B-protein
inhibitor	I-protein
of	O
NF-kappaB	B-protein
(	O
IkappaB-alphaS32/36A	B-protein
)	O
and	O
the	O
implications	O
for	O
vaccine	O
development	O
.	O

Live-attenuated	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
are	O
candidates	O
for	O
Acquired	O
Immunodeficiency	O
Syndrome	O
(	O
AIDS	O
)	O
vaccine	O
.	O

Based	O
on	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
model	O
for	O
AIDS	O
,	O
loss-of-function	O
(	O
e.g.	O
deletion	O
of	O
accessory	O
genes	O
such	O
as	O
nef	B-DNA
)	O
has	O
been	O
forwarded	O
as	O
a	O
primary	O
approach	O
for	O
creating	O
enfeebled	O
,	O
but	O
replication-competent	O
,	O
HIV-1/SIV	O
.	O

Regrettably	O
,	O
recent	O
evidence	O
suggests	O
that	O
loss-of-function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O

New	O
strategies	O
that	O
attenuate	O
via	O
mechanisms	O
distinct	O
from	O
loss-of-function	O
are	O
needed	O
for	O
enhancing	O
the	O
safety	O
phenotype	O
of	O
viral	B-DNA
genome	I-DNA
.	O

Here	O
,	O
we	O
propose	O
gain-of-function	O
to	O
be	O
used	O
simultaneously	O
with	O
loss-of-function	O
as	O
a	O
novel	O
approach	O
for	O
attenuating	O
HIV-1	O
.	O

We	O
have	O
constructed	O
an	O
HIV-1	B-DNA
genome	I-DNA
carrying	O
the	O
cDNA	B-DNA
of	O
a	O
proteolysis-resistant	B-protein
nuclear	I-protein
factor-kappaB	I-protein
inhibitor	I-protein
(	O
IkappaB-alphaS32/36A	B-protein
)	O
in	O
the	O
nef	B-DNA
region	I-DNA
.	O

HIV-1	O
expressing	O
IkappaB-alphaS32/36A	B-protein
down-regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	O
in	O
both	O
Jurkat	B-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

We	O
provide	O
formal	O
proof	O
that	O
the	O
phenotypic	O
and	O
attenuating	O
characteristics	O
of	O
IkappaB-alphaS32/36A	B-protein
permit	O
its	O
stable	O
maintenance	O
in	O
a	O
live	O
,	O
replicating	O
HIV-1	O
despite	O
180	O
days	O
of	O
forced	O
ex	O
vivo	O
passaging	O
in	O
tissue	O
culture	O
.	O

As	O
compared	O
with	O
other	O
open-reading	B-DNA
frames	I-DNA
embedded	O
into	O
HIV/SIV	B-DNA
genome	I-DNA
,	O
this	O
degree	O
of	O
stability	O
is	O
unprecedented	O
.	O

Thus	O
,	O
IkappaB-alphaS32/36A	B-protein
offers	O
proof-of-principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV-1	O
,	O
can	O
be	O
stable	O
.	O

These	O
findings	O
illustrate	O
gain-of-function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live-attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
Vol	NULL
.	NULL

274	NULL
,	NULL
No	NULL
.	NULL

25	NULL
,	NULL
Issue	NULL
of	NULL
June	NULL
18	NULL
,	NULL
pp	NULL
.	NULL

17567-17572	NULL
,	NULL
1999	NULL
Printed	NULL
in	NULL
U.S.A	NULL
.	NULL

Potent	NULL
and	NULL
Stable	NULL
Attenuation	NULL
of	NULL
Live-HIV-1	NULL
by	NULL
Gain	NULL
of	NULL
a	NULL
Proteolysis-resistant	NULL
Inhibitor	NULL
of	NULL
NF-B	NULL
(	NULL
IxB-a	NULL
«	NULL
832/36A	NULL
)	NULL
and	NULL
the	NULL
Implications	NULL
for	NULL
Vaccine	NULL
Development*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
February	NULL
25	NULL
,	NULL
1999	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
April	NULL
7	NULL
,	NULL
1999	NULL
)	NULL
Ileana	NULL
Quinto	NULL
$	NULL
§1	NULL
,	NULL
Massimo	NULL
Mallardo	NULL
#	NULL
,	NULL
Francesca	NULL
Baldassarre	NULL
?	NULL

#	NULL
]	NULL
,	NULL
Giuseppe	NULL
Scalaf	NULL
$	NULL
§	NULL
,	NULL
George	NULL
Englund**	NULL
,	NULL
and	NULL
Kuan-Teh	NULL
Jeang**	NULL
From	NULL
the	NULL
{	NULL
Dipartimento	NULL
di	NULL
Biochimica	NULL
e	NULL
Biotecnologie	NULL
Mediche	NULL
,	NULL
Université	NULL
degli	NULL
Studi	NULL
di	NULL
Napoli	NULL
``	NULL
Federico	NULL
II	NULL
``	NULL
,	NULL
Napoli	NULL
I-80131	NULL
,	NULL
Italy	NULL
,	NULL
the	NULL
**Dipartimento	NULL
di	NULL
Medicina	NULL
Sperimentale	NULL
e	NULL
Clinica	NULL
,	NULL
Universita	NULL
degli	NULL
Studi	NULL
di	NULL
Catanzaro	NULL
,	NULL
Catanzaro	NULL
I-88100	NULL
Italy	NULL
,	NULL
and	NULL
the	NULL
||Laboratory	NULL
of	NULL
Molecular	NULL
Microbiology	NULL
,	NULL
NIAID	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892-0460	NULL
Live-attenuated	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
(	NULL
HIVs	NULL
)	NULL
are	NULL
candidates	NULL
for	NULL
Acquired	NULL
Immunodeficiency	NULL
Syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
vaccine	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
SIV	NULL
)	NULL
model	NULL
for	NULL
AIDS	NULL
,	NULL
loss-of-function	NULL
(	NULL
e.g	NULL
.	NULL

deletion	NULL
of	NULL
accessory	NULL
genes	NULL
such	NULL
as	NULL
nef	NULL
)	NULL
has	NULL
been	NULL
forwarded	NULL
as	NULL
a	NULL
primary	NULL
approach	NULL
for	NULL
creating	NULL
enfeebled	NULL
,	NULL
but	NULL
replication-competent	NULL
,	NULL
HIV-1/SIV	NULL
.	NULL

Regrettably	NULL
,	NULL
recent	NULL
evidence	NULL
suggests	NULL
that	NULL
loss-of-function	NULL
alone	NULL
is	NULL
not	NULL
always	NULL
sufficient	NULL
to	NULL
prevent	NULL
the	NULL
emergence	NULL
of	NULL
virulent	NULL
mutants	NULL
.	NULL

New	NULL
strategies	NULL
that	NULL
attenuate	NULL
via	NULL
mechanisms	NULL
distinct	NULL
from	NULL
loss-of-function	NULL
are	NULL
needed	NULL
for	NULL
enhancing	NULL
the	NULL
safety	NULL
phenotype	NULL
of	NULL
viral	NULL
genome	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
propose	NULL
gain-of-function	NULL
to	NULL
be	NULL
used	NULL
simultaneously	NULL
with	NULL
loss-of-function	NULL
as	NULL
a	NULL
novel	NULL
approach	NULL
for	NULL
attenuating	NULL
HIV-1	NULL
.	NULL

We	NULL
have	NULL
constructed	NULL
an	NULL
HIV-1	NULL
genome	NULL
carrying	NULL
the	NULL
cDNA	NULL
of	NULL
a	NULL
proteolysis-resistant	NULL
nuclear	NULL
factor-	NULL
«	NULL
B	NULL
inhibitor	NULL
(	NULL
IxB-a832/36A	NULL
)	NULL
in	NULL
the	NULL
nef	NULL
region	NULL
.	NULL

HIV-1	NULL
expressing	NULL
IxB-	NULL
«	NULL
832/36A	NULL
down-regulates	NULL
viral	NULL
expression	NULL
and	NULL
is	NULL
highly	NULL
attenuated	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

We	NULL
provide	NULL
formal	NULL
proof	NULL
that	NULL
the	NULL
phenotypic	NULL
and	NULL
attenuating	NULL
characteristics	NULL
of	NULL
IxB-e	NULL
«	NULL
832/36A	NULL
permit	NULL
its	NULL
stable	NULL
maintenance	NULL
in	NULL
a	NULL
live	NULL
,	NULL
replicating	NULL
HIV-1	NULL
despite	NULL
180	NULL
days	NULL
of	NULL
forced	NULL
ex	NULL
vivo	NULL
passaging	NULL
in	NULL
tissue	NULL
culture	NULL
.	NULL

As	NULL
compared	NULL
with	NULL
other	NULL
open-reading	NULL
frames	NULL
embedded	NULL
into	NULL
HIV/SIV	NULL
genome	NULL
,	NULL
this	NULL
degree	NULL
of	NULL
stability	NULL
is	NULL
unprecedented	NULL
.	NULL

Thus	NULL
,	NULL
IxB-	NULL
«	NULL
832/36A	NULL
offers	NULL
proof-of-principle	NULL
that	NULL
artifactually	NULL
gained	NULL
functions	NULL
,	NULL
when	NULL
used	NULL
to	NULL
attenuate	NULL
the	NULL
replication	NULL
of	NULL
live	NULL
HIV-1	NULL
,	NULL
can	NULL
be	NULL
stable	NULL
.	NULL

These	NULL
findings	NULL
illustrate	NULL
gain-of-function	NULL
as	NULL
a	NULL
feasible	NULL
strategy	NULL
for	NULL
developing	NULL
safer	NULL
live-attenuated	NULL
HIVs	NULL
to	NULL
be	NULL
tested	NULL
as	NULL
candidates	NULL
for	NULL
AIDS	NULL
vaccine	NULL
.	NULL

Live-attenuated	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
,	NULL
type-l	NULL
(	NULL
HIV-1	NULL
)	NULL
'	NULL
viruses	NULL
are	NULL
vaccine	NULL
candidates	NULL
for	NULL
AIDS	NULL
based	NULL
on	NULL
the	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Ministero	NULL
della	NULL
Sanita-Istituto	NULL
Superiore	NULL
di	NULL
Sanita-Programma	NULL
Nazionale	NULL
di	NULL
Ricerca	NULL
sull'AIDS	NULL
Grant	NULL
40A.0.85	NULL
,	NULL
by	NULL
Pediatric	NULL
AIDS	NULL
Foundation	NULL
Grant	NULL
PS-22055	NULL
,	NULL
and	NULL
by	NULL
the	NULL
AIDS	NULL
Antiviral	NULL
Targeted	NULL
program	NULL
from	NULL
the	NULL
Office	NULL
of	NULL
the	NULL
Director	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
17834	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

|	NULL
Recipient	NULL
of	NULL
a	NULL
fellowship	NULL
from	NULL
Istituto	NULL
Superiore	NULL
di	NULL
Sanita-Progetto	NULL
di	NULL
Ricerche	NULL
sullAIDS	NULL
.	NULL

«	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Dipartimento	NULL
di	NULL
Biochimica	NULL
E	NULL
Biotecnologie	NULL
Mediche	NULL
,	NULL
via	NULL
Sergio	NULL
Pansini	NULL
5	NULL
,	NULL
I-80181	NULL
Napoli	NULL
,	NULL
Italy	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
89-081-7463157	NULL
;	NULL
Fax	NULL
:	NULL
89-081-7468150	NULL
;	NULL
E-mail	NULL
:	NULL
quinto	NULL
@	NULL
dbbm.unina.it	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
HIV-1	NULL
,	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
,	NULL
type-1	NULL
;	NULL
SIV	NULL
,	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
;	NULL
AIDS	NULL
,	NULL
acquired	NULL
immuno-	NULL
This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
assumption	NULL
that	NULL
poorly	NULL
replicating	NULL
viruses	NULL
are	NULL
reduced	NULL
in	NULL
cy-topathicity	NULL
while	NULL
eliciting	NULL
an	NULL
efficient	NULL
immune	NULL
response	NULL
in	NULL
vivo	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
in	NULL
the	NULL
SIV	NULL
model	NULL
of	NULL
AIDS	NULL
,	NULL
viruses	NULL
deleted	NULL
of	NULL
accessory	NULL
genes	NULL
,	NULL
such	NULL
as	NULL
nef	NULL
,	NULL
are	NULL
attenuated	NULL
and	NULL
confer	NULL
immune	NULL
protection	NULL
in	NULL
adults	NULL
(	NULL
1-6	NULL
)	NULL
.	NULL

Recent	NULL
results	NULL
have	NULL
raised	NULL
concerns	NULL
about	NULL
the	NULL
safety	NULL
of	NULL
such	NULL
live-attenuated	NULL
viruses	NULL
because	NULL
of	NULL
the	NULL
emergence	NULL
of	NULL
virulent	NULL
mutants	NULL
(	NULL
7-11	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
it	NULL
is	NULL
reasonable	NULL
that	NULL
new	NULL
mechanistically	NULL
distinct	NULL
strategies	NULL
should	NULL
be	NULL
considered	NULL
in	NULL
combination	NULL
with	NULL
loss-of-function	NULL
to	NULL
develop	NULL
safe	NULL
live-attenuated	NULL
vaccine	NULL
candidates	NULL
.	NULL

Stable	NULL
attenuation	NULL
of	NULL
lentivirus	NULL
is	NULL
difficult	NULL
.	NULL

Reasons	NULL
for	NULL
this	NULL
include	NULL
the	NULL
high	NULL
mutability	NULL
of	NULL
retroviruses	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
poor	NULL
fidelity	NULL
in	NULL
reverse	NULL
transcription	NULL
and	NULL
high	NULL
rates	NULL
of	NULL
viral	NULL
replication	NULL
.	NULL

Virus	NULL
replication	NULL
is	NULL
one	NULL
of	NULL
several	NULL
parameters	NULL
used	NULL
to	NULL
measure	NULL
HIV	NULL
disease	NULL
progres-sion	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
endowing	NULL
the	NULL
viral	NULL
genome	NULL
with	NULL
an	NULL
inhibitory	NULL
function	NULL
that	NULL
represses	NULL
replication	NULL
is	NULL
,	NULL
in	NULL
principle	NULL
,	NULL
a	NULL
valid	NULL
strategy	NULL
for	NULL
attenuation	NULL
.	NULL

AIDS	NULL
pathogenesis	NULL
involves	NULL
complex	NULL
host-pathogen	NULL
interactions	NULL
(	NULL
12-17	NULL
)	NULL
.	NULL

HIV-1	NULL
entry	NULL
occurs	NULL
through	NULL
binding	NULL
of	NULL
gp120	NULL
envelope	NULL
glycoprotein	NULL
to	NULL
CD4	NULL
and	NULL
chemokine	NULL
co-receptors	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Later	NULL
,	NULL
after	NULL
reverse	NULL
transcription	NULL
and	NULL
integration	NULL
,	NULL
regulated	NULL
HIV-1	NULL
gene	NULL
expression	NULL
is	NULL
dependent	NULL
on	NULL
cellular	NULL
transcription	NULL
factors	NULL
and	NULL
on	NULL
the	NULL
viral	NULL
Tat	NULL
protein	NULL
acting	NULL
through	NULL
several	NULL
cis	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Prominent	NULL
among	NULL
these	NULL
sequences	NULL
are	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
Sp1-TATAA	NULL
motif	NULL
(	NULL
22	NULL
)	NULL
and	NULL
a	NULL
third	NULL
NF-KB	NULL
site	NULL
co-incident	NULL
with	NULL
the	NULL
TAR	NULL
sequence	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
prevalence	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
all	NULL
HIV	NULL
isolates	NULL
(	NULL
24	NULL
)	NULL
suggests	NULL
that	NULL
NF-kB	NULL
function	NULL
is	NULL
fundamentally	NULL
important	NULL
for	NULL
virus	NULL
replication	NULL
and	NULL
represents	NULL
an	NULL
attractive	NULL
target	NULL
to	NULL
attenuate	NULL
HIVs	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
regulated	NULL
by	NULL
IB	NULL
inhibitors	NULL
(	NULL
25	NULL
)	NULL
.	NULL

In	NULL
response	NULL
to	NULL
activating	NULL
stimuli	NULL
,	NULL
IB	NULL
proteins	NULL
become	NULL
phosphorylated	NULL
,	NULL
ubiquinated	NULL
,	NULL
and	NULL
degraded	NULL
by	NULL
protea-somes	NULL
.	NULL

This	NULL
releases	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
leading	NULL
to	NULL
tran-scriptional	NULL
activation	NULL
of	NULL
responsive	NULL
genes	NULL
.	NULL

An	NULL
IkB-a	NULL
mutant	NULL
protein	NULL
,	NULL
(	NULL
defective	NULL
for	NULL
serine	NULL
32-	NULL
and	NULL
serine	NULL
36-phosphorylation	NULL
)	NULL
,	NULL
was	NULL
previously	NULL
shown	NULL
to	NULL
resist	NULL
proteolysis	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

IxB-e832/36A	NULL
was	NULL
found	NULL
to	NULL
be	NULL
a	NULL
particularly	NULL
potent	NULL
inhibitor	NULL
of	NULL
NF-	NULL
«	NULL
B-dependent	NULL
gene	NULL
transcription	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
role	NULL
of	NULL
NF-KB	NULL
in	NULL
virus	NULL
transcription	NULL
,	NULL
we	NULL
reasoned	NULL
that	NULL
expression	NULL
of	NULL
I	NULL
«	NULL
B-	NULL
«	NULL
832/36A	NULL
could	NULL
be	NULL
one	NULL
way	NULL
to	NULL
attenuate	NULL
HIV-1	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
feasibility	NULL
of	NULL
a	NULL
stable	NULL
bimodal	NULL
attenuation	NULL
of	NULL
HIV-1	NULL
through	NULL
both	NULL
gain-	NULL
and	NULL
loss-of-function	NULL
.	NULL

deficiency	NULL
syndrome	NULL
;	NULL
LTR	NULL
,	NULL
long	NULL
terminal	NULL
repeat	NULL
;	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
;	NULL
RT	NULL
,	NULL
reverse	NULL
transcriptase	NULL
;	NULL
PCR	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
PBMC	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
;	NULL
nt	NULL
,	NULL
nucleotide	NULL
(	NULL
s	NULL
)	NULL
;	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
.	NULL

17567	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
17568	NULL
A	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Recombinant	NULL
HIV-1	NULL
viruses	NULL
that	NULL
express	NULL
IxB-a	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
structure	NULL
HIV-1	NULL
Attenuation	NULL
by	NULL
Gain	NULL
of	NULL
IxB-	NULL
«	NULL
832/36A	NULL
Function	NULL
+1	NULL
+078	NULL
IxB-a	NULL
wild-type	NULL
”	NULL
En—+1	NULL
Ix	NULL
B-a	NULL
$	NULL
32/36A	NULL
anti-sense	NULL
+1	NULL
+978	NULL
Ix	NULL
B-	NULL
a	NULL
$	NULL
32/86A	NULL
of	NULL
HIV-1	NULL
genomes	NULL
that	NULL
express	NULL
I	NULL
«	NULL
B-	NULL
@	NULL
wﬁD—m	NULL
wild-type	NULL
(	NULL
pNLIkB-wt	NULL
)	NULL
,	NULL
IxB-a832/86A	NULL
in	NULL
sense	NULL
(	NULL
pNLI	NULL
«	NULL
B-M	NULL
)	NULL
,	NULL
and	NULL
antisense	NULL
(	NULL
pNLI	NULL
«	NULL
B-as	NULL
)	NULL
orientations	NULL
,	NULL
respectively	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
immunoblot	NULL
analysis	NULL
of	NULL
total	NULL
extracts	NULL
(	NULL
10	NULL
ug	NULL
each	NULL
)	NULL
from	NULL
2983T	NULL
cells	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
with	NULL
the	NULL
indicated	NULL
B	NULL
e	NULL
C	NULL
&	NULL
o	NULL
&	NULL
HIV-1	NULL
plasmids	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
using	NULL
a	NULL
hyperim-	NULL
#	NULL
g	NULL
¢	NULL
_	NULL
&	NULL
&	NULL
&	NULL
mune	NULL
AIDS	NULL
patient	NULL
serum	NULL
.	NULL

Panel	NULL
C	NULL
,	NULL
im-	NULL
6	NULL
’	NULL
03	NULL
‘	NULL
b	NULL
“	NULL
?	NULL

045	NULL
``	NULL
04-0	NULL
of	NULL
”	NULL
es	NULL
?	NULL

y	NULL
``	NULL
Vvé	NULL
\v°i+	NULL
‘	NULL
¢	NULL
‘	NULL
;	NULL
\	NULL
>	NULL
+	NULL
munoblot	NULL
analysis	NULL
of	NULL
total	NULL
extracts	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
#	NULL
FF	NULL
F	NULL
F	NULL
F	NULL
S	NULL
4	NULL
9	NULL
x	NULL
&	NULL
|	NULL
from	NULL
2983T	NULL
cells	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
MW	NULL
with	NULL
the	NULL
indicated	NULL
HIV-1	NULL
plasmids	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
using	NULL
anti-FLAG	NULL
monoclonal	NULL
antibody	NULL
followed	NULL
by	NULL
an	NULL
anti-I	NULL
«	NULL
B-	NULL
@	NULL
«	NULL
antiserum	NULL
.	NULL

This	NULL
66	NULL
mixture	NULL
identifies	NULL
both	NULL
IxB-a-FLAG	NULL
ex	NULL
pressed	NULL
from	NULL
the	NULL
viral	NULL
genomes	NULL
and	NULL
en-	NULL
46	NULL
dogenous	NULL
IxB-a	NULL
.	NULL

30	NULL
_	NULL
21.5	NULL
_	NULL
We	NULL
show	NULL
that	NULL
a	NULL
proteolysis-resistant	NULL
dominant	NULL
negative	NULL
IkB-a	NULL
molecule	NULL
(	NULL
IxB-a832/36A	NULL
)	NULL
can	NULL
be	NULL
inserted	NULL
into	NULL
nef	NULL
of	NULL
HIV-1	NULL
,	NULL
is	NULL
maintained	NULL
in	NULL
the	NULL
viral	NULL
genome	NULL
despite	NULL
prolonged	NULL
passaging	NULL
in	NULL
tissue	NULL
culture	NULL
,	NULL
and	NULL
contributes	NULL
to	NULL
a	NULL
strong	NULL
attenuation	NULL
of	NULL
HIV-1	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
gain-of-function	NULL
should	NULL
be	NULL
considered	NULL
together	NULL
with	NULL
loss-of-function	NULL
in	NULL
strategies	NULL
for	NULL
constructing	NULL
safe	NULL
live-attenuated	NULL
HIV-1	NULL
vaccine	NULL
candidates	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
they	NULL
demonstrate	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
inhibition	NULL
is	NULL
a	NULL
major	NULL
target	NULL
for	NULL
HIV-1	NULL
attenuation	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Construction	NULL
of	NULL
IxB-a	NULL
Recombinant	NULL
HIV-1	NULL
Viruses-pNLAnef	NULL
was	NULL
generated	NULL
by	NULL
replacing	NULL
the	NULL
first	NULL
117	NULL
nucleotides	NULL
of	NULL
nef	NULL
sequence	NULL
of	NULL
pNL4-38	NULL
(	NULL
28	NULL
)	NULL
with	NULL
a	NULL
linker	NULL
specifying	NULL
for	NULL
the	NULL
unique	NULL
restriction	NULL
sites	NULL
Xhol	NULL
,	NULL
Xbal	NULL
,	NULL
and	NULL
NotI	NULL
.	NULL

This	NULL
resulted	NULL
in	NULL
the	NULL
frameshift	NULL
of	NULL
the	NULL
remaining	NULL
nef	NULL
sequence	NULL
.	NULL

cDNAs	NULL
for	NULL
IxB-	NULL
@	NULL
and	NULL
IxB-a882/86A	NULL
were	NULL
amplified	NULL
by	NULL
PCR	NULL
using	NULL
a	NULL
5'-primer	NULL
flanked	NULL
by	NULL
Soil	NULL
site	NULL
and	NULL
a	NULL
3'-primer	NULL
flanked	NULL
by	NULL
the	NULL
FLAG	NULL
sequence	NULL
followed	NULL
by	NULL
stop	NULL
codon	NULL
and	NULL
Xbal	NULL
site	NULL
.	NULL

The	NULL
5'-primer	NULL
was	NULL
5'-ACGCGTCGACATGTTCCAGGCGGCCGAGCGC-3	NULL
'	NULL
;	NULL
the	NULL
3'-primer	NULL
was	NULL
5'-GCTCTAGATCACTTGTCGTCATCGTCTTTGTAGTCT-AACGTCAGACGCTGGCCTCCAAA-3	NULL
'	NULL
.	NULL

The	NULL
PCR	NULL
products	NULL
for	NULL
IxB-a	NULL
and	NULL
IxB-	NULL
@	NULL
882/36A	NULL
were	NULL
digested	NULL
with	NULL
Sail	NULL
and	NULL
Xbal	NULL
and	NULL
ligated	NULL
into	NULL
pNLAnef	NULL
to	NULL
generate	NULL
pNLIkB-wt	NULL
and	NULL
pNLIxB-M	NULL
,	NULL
respectively	NULL
.	NULL

I	NULL
«	NULL
B-was	NULL
also	NULL
cloned	NULL
in	NULL
antisense	NULL
orientation	NULL
using	NULL
a	NULL
5'-primer	NULL
flanked	NULL
by	NULL
Xbal	NULL
site	NULL
and	NULL
a	NULL
3'-primer	NULL
flanked	NULL
by	NULL
Sail	NULL
site	NULL
to	NULL
generate	NULL
pNLIxB-as	NULL
.	NULL

Molecular	NULL
clones	NULL
were	NULL
confirmed	NULL
by	NULL
DNA	NULL
restriction	NULL
analysis	NULL
and	NULL
DNA	NULL
sequencing	NULL
.	NULL

Transfections	NULL
and	NULL
Viral	NULL
Stocks-298T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
Dulbec-co	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
v/v	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
3	NULL
mM	NULL
glutamine	NULL
.	NULL

Viral	NULL
stocks	NULL
were	NULL
produced	NULL
by	NULL
transfecting	NULL
2983T	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
with	NULL
viral	NULL
plasmids	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
using	NULL
calcium	NULL
phosphate	NULL
.	NULL

Forty	NULL
hours	NULL
later	NULL
,	NULL
the	NULL
cell	NULL
culture	NULL
superna-tant	NULL
was	NULL
passed	NULL
through	NULL
a	NULL
0.45-um	NULL
filter	NULL
and	NULL
measured	NULL
for	NULL
RT	NULL
activity	NULL
.	NULL

Immunoblot	NULL
Analysis-298T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
viral	NULL
plasmids	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
were	NULL
lysed	NULL
in	NULL
RIPA	NULL
buffer	NULL
24	NULL
h	NULL
later	NULL
.	NULL

Proteins	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
in	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
Immobilon-P	NULL
(	NULL
Millipore	NULL
)	NULL
.	NULL

Filters	NULL
were	NULL
blotted	NULL
with	NULL
AIDS	NULL
patient	NULL
serum	NULL
or	NULL
with	NULL
anti-FLAG	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Eastman	NULL
Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
and	NULL
anti-IxB-a	NULL
antiserum	NULL
recognizing	NULL
the	NULL
amino	NULL
acids	NULL
51-64	NULL
of	NULL
IxB-a	NULL
(	NULL
gift	NULL
from	NULL
N.	NULL
Rice	NULL
,	NULL
National	NULL
Cancer	NULL
Institute-Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
MD	NULL
)	NULL
using	NULL
West-ern-Light	NULL
Chemiluminescent	NULL
Detection	NULL
System	NULL
(	NULL
Tropix	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

RNase	NULL
Protection	NULL
Assay-298T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
viral	NULL
plasmids	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
using	NULL
calcium	NULL
phosphate	NULL
,	NULL
and	NULL
total	NULL
RNA	NULL
was	NULL
isolated	NULL
by	NULL
acid	NULL
guanidinium	NULL
thiocyanate/phenol/chloroform	NULL
extraction	NULL
3	NULL
days	NULL
after	NULL
transfection	NULL
.	NULL

RNA	NULL
was	NULL
treated	NULL
with	NULL
RQ1	NULL
DNase	NULL
from	NULL
Promega	NULL
(	NULL
2	NULL
IxB-a	NULL
FLAG	NULL
Ix	NULL
B-a	NULL
8	NULL
4	NULL
5006	NULL
102	NULL
:	NULL
4	NULL
506	NULL
units/50	NULL
ug	NULL
of	NULL
RNA	NULL
)	NULL
at	NULL
87	NULL
°C	NULL
for	NULL
15	NULL
min	NULL
,	NULL
extracted	NULL
by	NULL
phenol	NULL
:	NULL
chloroform	NULL
(	NULL
25:24	NULL
)	NULL
and	NULL
precipitated	NULL
in	NULL
ethanol	NULL
.	NULL

RNase	NULL
protection	NULL
assay	NULL
was	NULL
performed	NULL
using	NULL
RPA	NULL
II	NULL
kit	NULL
(	NULL
Ambion	NULL
,	NULL
Austin	NULL
,	NULL
TX	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
aliquots	NULL
of	NULL
10	NULL
ug	NULL
of	NULL
RNA	NULL
from	NULL
different	NULL
samples	NULL
were	NULL
hybridized	NULL
with	NULL
10°	NULL
cpm	NULL
of	NULL
HIV-1	NULL
and	NULL
actin	NULL
RNA	NULL
probes	NULL
for	NULL
15	NULL
h	NULL
at	NULL
44	NULL
°C	NULL
.	NULL

Yeast	NULL
RNA	NULL
was	NULL
used	NULL
as	NULL
control	NULL
.	NULL

Samples	NULL
were	NULL
treated	NULL
with	NULL
RNase	NULL
A	NULL
(	NULL
2.5	NULL
units/ml	NULL
)	NULL
and	NULL
RNase	NULL
T1	NULL
(	NULL
100	NULL
units/ml	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
,	NULL
precipitated	NULL
in	NULL
ethanol	NULL
,	NULL
resuspended	NULL
in	NULL
gel	NULL
loading	NULL
buffer	NULL
(	NULL
95	NULL
%	NULL
formamide	NULL
,	NULL
0.025	NULL
%	NULL
xylene	NULL
cyanol	NULL
,	NULL
0.025	NULL
%	NULL
brom-phenol	NULL
blue	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.025	NULL
%	NULL
SDS	NULL
)	NULL
,	NULL
and	NULL
separated	NULL
by	NULL
electrophoresis	NULL
on	NULL
8	NULL
M	NULL
urea	NULL
,	NULL
8	NULL
%	NULL
acrylamide	NULL
gel	NULL
in	NULL
Tris	NULL
borate-EDTA	NULL
.	NULL

HIV-1	NULL
antisense	NULL
probe	NULL
to	NULL
the	NULL
pNL4-3	NULL
sequence	NULL
from	NULL
+350	NULL
to	NULL
+535	NULL
nt	NULL
corresponding	NULL
to	NULL
NF-kB	NULL
,	NULL
Sp1	NULL
,	NULL
TATAA	NULL
,	NULL
and	NULL
TAR	NULL
sequences	NULL
of	NULL
HIV-1	NULL
LTR	NULL
was	NULL
transcribed	NULL
from	NULL
the	NULL
T7	NULL
promoter	NULL
in	NULL
the	NULL
pGEM	NULL
LTR	NULL
vector	NULL
.	NULL

Protected	NULL
HIV-1-specific	NULL
bands	NULL
of	NULL
80	NULL
and	NULL
185	NULL
bp	NULL
correspond	NULL
to	NULL
the	NULL
5'-LTR	NULL
(	NULL
+455	NULL
to	NULL
+585	NULL
nt	NULL
of	NULL
pNL4-S	NULL
sequence	NULL
)	NULL
and	NULL
the	NULL
3'-LTR	NULL
(	NULL
+9425	NULL
to	NULL
+9610	NULL
nt	NULL
of	NULL
pNL4-3	NULL
sequence	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Actin	NULL
antisense	NULL
probe	NULL
was	NULL
transcribed	NULL
using	NULL
T7	NULL
RNA-polymerase	NULL
from	NULL
vector	NULL
pTRI-B-actin-125-human	NULL
(	NULL
Am-bion	NULL
)	NULL
.	NULL

Protected	NULL
actin	NULL
transcript	NULL
corresponds	NULL
to	NULL
a	NULL
band	NULL
of	NULL
127	NULL
bp	NULL
.	NULL

T7	NULL
RNA	NULL
polymerase-derived	NULL
transcripts	NULL
were	NULL
produced	NULL
by	NULL
using	NULL
the	NULL
Ribo-probe	NULL
in	NULL
vitro	NULL
Transcription	NULL
System	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
were	NULL
normalized	NULL
to	NULL
CAT	NULL
activity	NULL
measured	NULL
from	NULL
co-transfections	NULL
with	NULL
pBLCAT2	NULL
(	NULL
2	NULL
pg	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
cat	NULL
gene	NULL
fused	NULL
to	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
£4	NULL
minimal	NULL
promoter	NULL
,	NULL
followed	NULL
by	NULL
CAT	NULL
assay	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Luciferase	NULL
Assay-Jurkat	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
co-transfected	NULL
with	NULL
pNL-Luc-R	NULL
E-	NULL
plasmid	NULL
(	NULL
29	NULL
)	NULL
(	NULL
1	NULL
pg	NULL
)	NULL
and	NULL
pNLIxB-as	NULL
or	NULL
pNLIxB-M	NULL
plasmids	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
using	NULL
Superfect	NULL
Reagent	NULL
(	NULL
Qiagen	NULL
,	NULL
Valencia	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Amounts	NULL
of	NULL
transfected	NULL
DNA	NULL
were	NULL
equalized	NULL
with	NULL
peDNA8.1	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
v/v	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
3	NULL
mM	NULL
glutamine	NULL
with	NULL
soluble	NULL
CD4	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
to	NULL
inhibit	NULL
multiple	NULL
rounds	NULL
of	NULL
infection	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
at	NULL
24	NULL
,	NULL
48	NULL
,	NULL
and	NULL
72	NULL
h	NULL
post-transfection	NULL
and	NULL
analyzed	NULL
for	NULL
luciferase	NULL
activity	NULL
using	NULL
Luciferase	NULL
Assay	NULL
System	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Viral	NULL
Growth-Jurkat	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
v/v	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
3	NULL
mM	NULL
glutamine	NULL
.	NULL

PBMCs	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
or	NULL
mAb	NULL
OKT3	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
v/v	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
for	NULL
3	NULL
days	NULL
and	NULL
then	NULL
washed	NULL
and	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
with	NULL
interleukin-2	NULL
(	NULL
20	NULL
units/ml	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
infected	NULL
with	NULL
equivalent	NULL
doses	NULL
of	NULL
viral	NULL
stocks	NULL
normalized	NULL
by	NULL
RT	NULL
activity	NULL
.	NULL

Cell	NULL
supernatants	NULL
were	NULL
collected	NULL
every	NULL
3	NULL
days	NULL
for	NULL
RT	NULL
assay	NULL
;	NULL
equal	NULL
volumes	NULL
of	NULL
fresh	NULL
medium	NULL
were	NULL
replaced	NULL
into	NULL
the	NULL
cultures	NULL
at	NULL
the	NULL
same	NULL
time	NULL
.	NULL

RT-PCR	NULL
Analysis-Viral	NULL
RNA	NULL
was	NULL
purified	NULL
from	NULL
cell	NULL
culture	NULL
supernatants	NULL
using	NULL
QIAampViral	NULL
RNA	NULL
kit	NULL
(	NULL
Qiagen	NULL
)	NULL
.	NULL

RNA	NULL
extracts	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
were	NULL
reverse	NULL
transcribed	NULL
,	NULL
and	NULL
PCR	NULL
was	NULL
amplified	NULL
using	NULL
Titan	NULL
One	NULL
Tube	NULL
RT-PCR	NULL
System	NULL
(	NULL
Roche	NULL
Molecular	NULL
Biochemicals	NULL
)	NULL
.	NULL

The	NULL
IxB-a8832/86A	NULL
sequence	NULL
was	NULL
amplified	NULL
with	NULL
primers	NULL
flanking	NULL
the	NULL
cDNA	NULL
insert	NULL
from	NULL
+8782	NULL
to	NULL
+8749	NULL
nt	NULL
(	NULL
5'-primer	NULL
;	NULL
env	NULL
region	NULL
)	NULL
and	NULL
from	NULL
+9017	NULL
to	NULL
+9084	NULL
nt	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
HIV-1	NULL
Attenuation	NULL
by	NULL
Gain	NULL
of	NULL
IxB-	NULL
«	NULL
832/36A	NULL
Function	NULL
A	NULL
&	NULL
Nx	NULL
22	NULL
«	NULL
*	NULL
%	NULL
«	NULL
9°	NULL
?	NULL

th	NULL
C5	NULL
4	NULL
RNase	NULL
-	NULL
+0	NULL
+	NULL
+	NULL
4	NULL
+	NULL
+	NULL
+	NULL
+	NULL
185	NULL
bp	NULL
-	NULL
w	NULL
-	NULL
3	NULL
``	NULL
LTR	NULL
80	NULL
bp	NULL
-	NULL
Wha	NULL
»	NULL
-	NULL
wwW	NULL
(	NULL
=	NULL
-5	NULL
LTR	NULL
%	NULL
>	NULL
#	NULL
1	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
CHDP	NULL
=	NULL
’	NULL
apaa	NULL
-	NULL
act	NULL
``	NULL
1	NULL
2	NULL
s	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
fae	NULL
:	NULL
C	NULL
pNL-Luc-E	NULL
-R-	NULL
+	NULL
peDNA3.1	NULL
500	NULL
F	NULL
pNL-Luc-E	NULL
~R	NULL
+	NULL
pNLI	NULL
«	NULL
B-as	NULL
(	NULL
Z	NULL
pNL-Luc-E	NULL
``	NULL
R*	NULL
+	NULL
pNLI	NULL
<	NULL
B-M	NULL
400	NULL
300	NULL
200	NULL
Luciferase	NULL
activity	NULL
100	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

IxB-	NULL
«	NULL
832/36A	NULL
represses	NULL
HIV-1	NULL
LTR-directed	NULL
transcrip-tion	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
298T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
indicated	NULL
viral	NULL
plasmids	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
were	NULL
normalized	NULL
based	NULL
on	NULL
the	NULL
co-transfection	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
pBLCAT2	NULL
.	NULL

Total	NULL
RNAs	NULL
were	NULL
quantitated	NULL
by	NULL
RNase	NULL
protection	NULL
assay	NULL
72	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Viral	NULL
RNAs	NULL
were	NULL
measured	NULL
as	NULL
3'-LTR	NULL
and	NULL
5'-LTR	NULL
protected	NULL
fragments	NULL
.	NULL

Cellular	NULL
actin-mRNA	NULL
was	NULL
quantitated	NULL
in	NULL
parallel	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
RNA	NULL
probe	NULL
plus	NULL
yeast	NULL
RNA	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
RNase	NULL
treatment	NULL
of	NULL
RNA	NULL
probe	NULL
plus	NULL
yeast	NULL
RNA	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
RNase	NULL
treatment	NULL
of	NULL
RNA	NULL
probe	NULL
plus	NULL
RNA	NULL
from	NULL
cells	NULL
transfected	NULL
only	NULL
with	NULL
pBLCAT2	NULL
.	NULL

Lanes	NULL
4-8	NULL
,	NULL
RNase	NULL
treatment	NULL
of	NULL
RNA	NULL
probe	NULL
plus	NULL
RNA	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
pNL4-3	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
,	NULL
pNLAnef	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
,	NULL
pNLIxB-M	NULL
(	NULL
Zane	NULL
6	NULL
)	NULL
,	NULL
pNLIxB-as	NULL
(	NULL
Zane	NULL
7	NULL
)	NULL
,	NULL
and	NULL
pNLIxB-wt	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Lane	NULL
9	NULL
,	NULL
sample	NULL
as	NULL
in	NULL
lane	NULL
6	NULL
with	NULL
a	NULL
10-fold	NULL
longer	NULL
exposure	NULL
.	NULL

CAT	NULL
activities	NULL
,	NULL
measured	NULL
as	NULL
percent	NULL
acetylation	NULL
of	NULL
per	NULL
50	NULL
ug	NULL
of	NULL
protein	NULL
per	NULL
3	NULL
h	NULL
,	NULL
from	NULL
lame	NULL
3-8	NULL
were	NULL
:	NULL
1.5	NULL
,	NULL
1.7	NULL
,	NULL
1.0	NULL
,	NULL
1.6	NULL
,	NULL
1.2	NULL
,	NULL
and	NULL
1.9	NULL
,	NULL
respectively	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
peDNA8.1	NULL
,	NULL
pNLI	NULL
«	NULL
B-as	NULL
,	NULL
or	NULL
pNLIxB-M	NULL
plasmids	NULL
(	NULL
5	NULL
pg	NULL
)	NULL
together	NULL
with	NULL
pNL-Luc-R	NULL
-	NULL
E-	NULL
reporter	NULL
plasmid	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
.	NULL

Luciferase	NULL
assay	NULL
was	NULL
performed	NULL
in	NULL
cell	NULL
lysates	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
.	NULL

Luciferase	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
arbitrary	NULL
light	NULL
units	NULL
per	NULL
100	NULL
ug	NULL
of	NULL
protein	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
8'-primer	NULL
;	NULL
nef	NULL
region	NULL
)	NULL
of	NULL
pNL4-8	NULL
.	NULL

As	NULL
control	NULL
,	NULL
the	NULL
integrase	NULL
region	NULL
was	NULL
amplified	NULL
with	NULL
5'-primer	NULL
from	NULL
+4389	NULL
to	NULL
+4859	NULL
nt	NULL
and	NULL
3'-primer	NULL
from	NULL
+4894	NULL
to	NULL
+4914	NULL
nt	NULL
of	NULL
pNL4-3	NULL
.	NULL

Amplification	NULL
was	NULL
carried	NULL
out	NULL
according	NULL
to	NULL
the	NULL
following	NULL
protocol	NULL
:	NULL
incubation	NULL
at	NULL
50	NULL
°C	NULL
for	NULL
30	NULL
min	NULL
,	NULL
preheating	NULL
at	NULL
95	NULL
°C	NULL
for	NULL
2	NULL
min	NULL
followed	NULL
by	NULL
30	NULL
cycles	NULL
of	NULL
95	NULL
°C	NULL
for	NULL
45	NULL
s	NULL
,	NULL
58	NULL
°C	NULL
for	NULL
45	NULL
s	NULL
,	NULL
and	NULL
72	NULL
°C	NULL
for	NULL
8	NULL
min	NULL
.	NULL

Flow	NULL
Cytometry	NULL
Analysis-Cells	NULL
were	NULL
stained	NULL
with	NULL
phycoerythrin-conjugated	NULL
anti-p24	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Ortho	NULL
Diagnostic	NULL
,	NULL
JURKAT	NULL
40000	NULL
40000	NULL
e	NULL
-o-	NULL
NL4-3	NULL
4	NULL
g	NULL
30000	NULL
30000	NULL
-*-	NULL
NLAnef	NULL
9	NULL
&	NULL
20000	NULL
20000	NULL
-*-	NULL
NLI	NULL
«	NULL
B-M	NULL
12	NULL
“	NULL
,	NULL
-*-	NULL
NLIxB-as	NULL
2	NULL
10000	NULL
10000	NULL
mock	NULL
cc	NULL
0	NULL
0	NULL
0	NULL
10	NULL
-	NULL
20	NULL
-	NULL
so	NULL
_	NULL
40	NULL
0	NULL
fo	NULL
-	NULL
20	NULL
_	NULL
30	NULL
_	NULL
40	NULL
Days	NULL
Days	NULL
OKT3-stimulated	NULL
PBMCs	NULL
15000	NULL
15000	NULL
#	NULL
-o-	NULL
NL4-3	NULL
S	NULL
g.	NULL
-*-	NULL
NLAnef	NULL
8	NULL
-	NULL
10000	NULL
10000	NULL
>	NULL
-*-	NULL
NLIxB-M	NULL
>	NULL
G	NULL
-	NULL
sooo	NULL
!	NULL

sooo	NULL
{	NULL
NLIxB-as	NULL
&	NULL
i-	NULL
-x-	NULL
mock	NULL
ra	NULL
a	NULL
=	NULL
50	NULL
do	NULL
50	NULL
_	NULL
20	NULL
o	NULL
500	NULL
o	NULL
i500	NULL
20	NULL
Days	NULL
Days	NULL
PHA-stimulated	NULL
PBMCs	NULL
20000	NULL
20000	NULL
a	NULL
-o-	NULL
NL4-3	NULL
72	NULL
``	NULL
15000	NULL
15000	NULL
°-	NULL
NLAnef	NULL
a.	NULL
C.	NULL
10000	NULL
10000	NULL
*~	NULL
NLIxB-M	NULL
E	NULL
-*-	NULL
NLIxB-as	NULL
g	NULL
=	NULL
sooo	NULL
5000	NULL
mock	NULL
i-	NULL
-*-ra	NULL
o	NULL
0	NULL
0	NULL
5	NULL
10	NULL
0	NULL
45	NULL
_	NULL
20	NULL
J	NULL
5	NULL
10	NULL
450	NULL
_	NULL
20	NULL
Days	NULL
Days	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

HIV-1	NULL
expressing	NULL
IxB-o832/36A	NULL
is	NULL
highly	NULL
attenuated	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
human	NULL
PBMCs	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
Jurkat	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
NL4-3	NULL
,	NULL
NLAnef	NULL
,	NULL
NLIkB-M	NULL
,	NULL
and	NULL
NLIxB-as	NULL
with	NULL
equal	NULL
amounts	NULL
of	NULL
viruses	NULL
normalized	NULL
based	NULL
on	NULL
RT	NULL
counts	NULL
of	NULL
10°	NULL
cpm	NULL
(	NULL
Zef	NULL
#	NULL
)	NULL
or	NULL
10°	NULL
cpm	NULL
(	NULL
right	NULL
)	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
PBMCs	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
stimulated	NULL
with	NULL
mAb	NULL
OKT3	NULL
were	NULL
infected	NULL
with	NULL
the	NULL
indicated	NULL
viruses	NULL
normalized	NULL
for	NULL
10°	NULL
cpm	NULL
(	NULL
left	NULL
)	NULL
or	NULL
10°	NULL
cpm	NULL
(	NULL
right	NULL
)	NULL
of	NULL
RT	NULL
.	NULL

Panel	NULL
C	NULL
,	NULL
PBMCs	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
stimulated	NULL
with	NULL
PHA	NULL
were	NULL
infected	NULL
with	NULL
viruses	NULL
normalized	NULL
for	NULL
10*	NULL
cpm	NULL
(	NULL
Zef	NULL
?	NULL
)	NULL

or	NULL
10°	NULL
cpm	NULL
(	NULL
right	NULL
)	NULL
of	NULL
RT	NULL
.	NULL

Viral	NULL
growth	NULL
was	NULL
measured	NULL
by	NULL
RT	NULL
activity	NULL
in	NULL
cell	NULL
culture	NULL
supernatants	NULL
.	NULL

Results	NULL
representative	NULL
of	NULL
six	NULL
independent	NULL
infections	NULL
are	NULL
shown	NULL
.	NULL

Raritan	NULL
,	NULL
NJ	NULL
)	NULL
and	NULL
Annexin-V-Fluos	NULL
(	NULL
Roche	NULL
Molecular	NULL
Biochemicals	NULL
)	NULL
.	NULL

Flow	NULL
cytometry	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
Coulter	NULL
Epics	NULL
XL	NULL
Cytometer	NULL
.	NULL

Ten	NULL
thousands	NULL
cells	NULL
were	NULL
analyzed	NULL
under	NULL
each	NULL
condition	NULL
.	NULL

RESULTS	NULL
HIV-1	NULL
Expressing	NULL
IxB-	NULL
«	NULL
832/36A	NULL
Down-regulates	NULL
Viral	NULL
Ex	NULL
pression-To	NULL
determine	NULL
whether	NULL
the	NULL
attenuation	NULL
of	NULL
HIV-1	NULL
could	NULL
be	NULL
obtained	NULL
via	NULL
cis-expression	NULL
of	NULL
a	NULL
proteolysis-resistant	NULL
inhibitor	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
FLAG-tagged	NULL
cDNA	NULL
was	NULL
positioned	NULL
in	NULL
sense	NULL
and	NULL
antisense	NULL
orientations	NULL
into	NULL
nef	NULL
of	NULL
HIV-1	NULL
pNL4-3	NULL
generating	NULL
pNLI	NULL
«	NULL
B-M	NULL
and	NULL
pNLIxB-as	NULL
genomes	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
an	NULL
otherwise	NULL
isogenic	NULL
molecular	NULL
clone	NULL
of	NULL
pNL4-3	NULL
expressing	NULL
the	NULL
proteolysis-sensitive	NULL
wild-type	NULL
I	NULL
«	NULL
xB-	NULL
«	NULL
cDNA	NULL
was	NULL
also	NULL
constructed	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

These	NULL
insertions	NULL
also	NULL
resulted	NULL
in	NULL
the	NULL
deletion	NULL
of	NULL
39	NULL
amino	NULL
acids	NULL
from	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
Nef	NULL
and	NULL
a	NULL
translational	NULL
frameshift	NULL
for	NULL
the	NULL
remaining	NULL
Nef-encoding	NULL
codons	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
chimeric	NULL
genomes	NULL
gained	NULL
an	NULL
I	NULL
«	NULL
B-	NULL
«	NULL
832/36A	NULL
function	NULL
coupled	NULL
with	NULL
a	NULL
simultaneous	NULL
loss	NULL
of	NULL
Nef	NULL
function	NULL
.	NULL

From	NULL
these	NULL
molecular	NULL
genomes	NULL
,	NULL
different	NULL
virus	NULL
stocks	NULL
were	NULL
generated	NULL
through	NULL
independent	NULL
transfections	NULL
of	NULL
293T	NULL
cells	NULL
.	NULL

Expression	NULL
in	NULL
the	NULL
transfected	NULL
cells	NULL
of	NULL
HIV-1	NULL
proteins	NULL
and	NULL
the	NULL
heterologous	NULL
I	NULL
«	NULL
B-cDNAs	NULL
was	NULL
verified	NULL
by	NULL
immunoblotting	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
functional	NULL
impact	NULL
of	NULL
IxB-	NULL
@	NULL
832/36A	NULL
in	NULL
the	NULL
context	NULL
of	NULL
HIV-1	NULL
gene	NULL
expres-sion	NULL
,	NULL
viral	NULL
transcription	NULL
in	NULL
293T	NULL
cells	NULL
transfected	NULL
individually	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
17570	NULL
with	NULL
pNL4-3	NULL
,	NULL
pNLAnef	NULL
,	NULL
pNLIxB-M	NULL
,	NULL
pNLIkB-as	NULL
,	NULL
or	NULL
pNLI	NULL
«	NULL
B-wt	NULL
was	NULL
analyzed	NULL
by	NULL
RNase	NULL
protection	NULL
assays	NULL
.	NULL

Viral	NULL
RNAs	NULL
were	NULL
efficiently	NULL
produced	NULL
from	NULL
all	NULL
genomes	NULL
except	NULL
for	NULL
the	NULL
I	NULL
«	NULL
B-	NULL
«	NULL
832¥/	NULL
36A-expressing	NULL
virus	NULL
,	NULL
pNLI	NULL
«	NULL
B-M	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
points	NULL
to	NULL
a	NULL
strong	NULL
inhibition	NULL
of	NULL
LTR-directed	NULL
transcription	NULL
by	NULL
«	NULL
832/36A	NULL
.	NULL

A	NULL
normalized	NULL
simultaneous	NULL
co-transfection	NULL
into	NULL
cells	NULL
of	NULL
genome	NULL
with	NULL
pNL4-3	NULL
genome	NULL
fused	NULL
to	NULL
the	NULL
Zucif-erase	NULL
reporter	NULL
gene	NULL
still	NULL
resulted	NULL
in	NULL
markedly	NULL
reduced	NULL
viral	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
inhibitory	NULL
mechanism	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
dominant	NULL
trans-repressive	NULL
effect	NULL
from	NULL
the	NULL
I	NULL
«	NULL
B-	NULL
«	NULL
832/36A	NULL
protein	NULL
rather	NULL
than	NULL
a	NULL
cis-destabilizing	NULL
phenomenon	NULL
arising	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
an	NULL
insertion	NULL
into	NULL
nef	NULL
.	NULL

This	NULL
is	NULL
further	NULL
supported	NULL
J	NULL
JURKAT	NULL
40000	NULL
40000	NULL
<	NULL
-*-	NULL
NLixB-as	NULL
s	NULL
§	NULL
-	NULL
sooo	NULL
20000	NULL
-	NULL
--	NULL
NLIxB-wt	NULL
o	NULL
~	NULL
-*-	NULL
NLIxB-M	NULL
p	NULL
-	NULL
200004	NULL
20000	NULL
>	NULL
-x-	NULL
mock	NULL
=	NULL
g	NULL
10000	NULL
10000	NULL
4	NULL
i-cc	NULL
tad	NULL
0	NULL
-|-m-fOG	NULL
CE	NULL
l	NULL
10	NULL
_	NULL
20	NULL
|	NULL
so	NULL
_	NULL
40	NULL
40	NULL
_	NULL
20	NULL
|	NULL
so	NULL
_	NULL
40	NULL
Days	NULL
Days	NULL
UJ	NULL
OKT3-stimulated	NULL
PBMCs	NULL
8000	NULL
2000	NULL
a	NULL
-4	NULL
&	NULL
-	NULL
NLIxB-as	NULL
el	NULL
g	NULL
=	NULL
00	NULL
4	NULL
-O-	NULL
NLixB-wt	NULL
a.	NULL
o	NULL
2	NULL
-e-	NULL
_	NULL
-	NULL
40004	NULL
40004	NULL
NLL	NULL
cB-M	NULL
B	NULL
-x-	NULL
mock	NULL
m	NULL
@	NULL
20004	NULL
2000	NULL
4	NULL
[	NULL
+d	NULL
04	NULL
o	NULL
5	NULL
10	NULL
-	NULL
15	NULL
_	NULL
20	NULL
5	NULL
40	NULL
0	NULL
1500	NULL
20	NULL
Days	NULL
Days	NULL
O	NULL
PHA-stimulated	NULL
PBMCs	NULL
8000	NULL
8000	NULL
a	NULL
-	NULL
&	NULL
-	NULL
NLlxB-as	NULL
3	NULL
E	NULL
6000	NULL
4	NULL
6000	NULL
4	NULL
NLIkB-wt	NULL
o	NULL
.	NULL

&	NULL
s	NULL
,	NULL
-	NULL
40004	NULL
40004	NULL
=	NULL
'	NULL
>	NULL
mock	NULL
E	NULL
{	NULL
20004	NULL
g	NULL
-	NULL
2000	NULL
fu	NULL
a	NULL
0	NULL
BTC	NULL
vind	NULL
¥	NULL
0	NULL
0	NULL
5	NULL
10	NULL
0	NULL
450	NULL
_	NULL
20	NULL
0	NULL
Days	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Wild-type	NULL
proteolysis-sensitive	NULL
IxB-a	NULL
poorly	NULL
attenuates	NULL
HIV-1	NULL
replication	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
pane	NULL
!	NULL

A	NULL
)	NULL
,	NULL
PBMCs	NULL
stimulated	NULL
with	NULL
mAb	NULL
OKT3	NULL
(	NULL
panel	NULL
B	NULL
)	NULL
,	NULL
and	NULL
PBMCs	NULL
stimulated	NULL
with	NULL
PHA	NULL
(	NULL
panel	NULL
!	NULL

C	NULL
)	NULL
were	NULL
infected	NULL
with	NULL
NLIxB-M	NULL
,	NULL
or	NULL
NLIxB-wt	NULL
viruses	NULL
and	NULL
measured	NULL
for	NULL
viral	NULL
production	NULL
as	NULL
detailed	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

HIV-1	NULL
Attenuation	NULL
by	NULL
Gain	NULL
of	NULL
IxB-	NULL
«	NULL
832/36A	NULL
Function	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
insertion	NULL
of	NULL
I	NULL
«	NULL
B-a	NULL
cDNA	NULL
either	NULL
in	NULL
antisense	NULL
orientation	NULL
,	NULL
or	NULL
as	NULL
wild-type	NULL
sequence	NULL
does	NULL
not	NULL
inhibit	NULL
viral	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Repressed	NULL
expression	NULL
would	NULL
have	NULL
been	NULL
expected	NULL
if	NULL
there	NULL
were	NULL
a	NULL
cis	NULL
insertional	NULL
effect	NULL
.	NULL

Attenuation	NULL
of	NULL
HIV-1	NULL
Expressing	NULL
IxB-	NULL
«	NULL
832/36A-Next	NULL
,	NULL
the	NULL
replication	NULL
properties	NULL
of	NULL
the	NULL
recombinant	NULL
HIV-1	NULL
genomes	NULL
were	NULL
measured	NULL
.	NULL

We	NULL
monitored	NULL
for	NULL
viral	NULL
growths	NULL
in	NULL
established	NULL
(	NULL
Ju-rkat	NULL
)	NULL
and	NULL
primary	NULL
(	NULL
PBMCs	NULL
)	NULL
T-cells	NULL
.	NULL

Based	NULL
on	NULL
normalized	NULL
amounts	NULL
of	NULL
input	NULL
viruses	NULL
,	NULL
NLI	NULL
«	NULL
B-M	NULL
was	NULL
found	NULL
to	NULL
be	NULL
highly	NULL
attenuated	NULL
in	NULL
Jurkat	NULL
cells	NULL
when	NULL
compared	NULL
with	NULL
the	NULL
NLAnef	NULL
and	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

A	NULL
reduced	NULL
replication	NULL
capacity	NULL
was	NULL
also	NULL
observed	NULL
for	NULL
NLI	NULL
«	NULL
B-M	NULL
in	NULL
human	NULL
PBMCs	NULL
stimulated	NULL
either	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
OKT3	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
or	NULL
PHA	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

In	NULL
par-allel	NULL
,	NULL
the	NULL
chimeric	NULL
HIV-1	NULL
which	NULL
expresses	NULL
the	NULL
proteolysis-sensitive	NULL
wild-type	NULL
IxB-a	NULL
produced	NULL
a	NULL
replication	NULL
profile	NULL
that	NULL
was	NULL
only	NULL
slightly	NULL
attenuated	NULL
when	NULL
compared	NULL
with	NULL
control	NULL
virus	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A-C	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
a	NULL
critical	NULL
contribution	NULL
of	NULL
proteolysis-resistant	NULL
mutant	NULL
I	NULL
«	NULL
B-a	NULL
«	NULL
toward	NULL
attenuated	NULL
viral	NULL
growth	NULL
.	NULL

Attenuation	NULL
of	NULL
NLIxB-M	NULL
Is	NULL
Not	NULL
Because	NULL
of	NULL
Apoptosis-Previ-ously	NULL
,	NULL
IxB-	NULL
«	NULL
832/36A	NULL
was	NULL
shown	NULL
to	NULL
enhance	NULL
the	NULL
apoptosis	NULL
induced	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
(	NULL
30-32	NULL
)	NULL
.	NULL

Because	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
is	NULL
produced	NULL
during	NULL
HIV-1	NULL
infection	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
,	NULL
we	NULL
asked	NULL
whether	NULL
a	NULL
pro-apoptotic	NULL
effect	NULL
of	NULL
IxB-a832/36A	NULL
might	NULL
account	NULL
,	NULL
in	NULL
part	NULL
,	NULL
for	NULL
attenuation	NULL
of	NULL
viral	NULL
growth	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
Jurkat	NULL
cells	NULL
infected	NULL
separately	NULL
with	NULL
NL4-3	NULL
,	NULL
NLIKB-M	NULL
,	NULL
or	NULL
NLI	NULL
«	NULL
B-as	NULL
viruses	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
p24	NULL
and	NULL
for	NULL
binding	NULL
to	NULL
annexin	NULL
V	NULL
,	NULL
a	NULL
marker	NULL
of	NULL
an	NULL
early	NULL
event	NULL
in	NULL
apoptosis	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
different	NULL
viral	NULL
growth	NULL
kinetics	NULL
,	NULL
to	NULL
account	NULL
fully	NULL
for	NULL
equivalent	NULL
levels	NULL
of	NULL
virus	NULL
production	NULL
,	NULL
cell	NULL
samples	NULL
were	NULL
analyzed	NULL
at	NULL
variant	NULL
times	NULL
post-infection	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
,	NULL
the	NULL
percentage	NULL
of	NULL
apoptotic	NULL
cells	NULL
among	NULL
p24-positive	NULL
population	NULL
was	NULL
17	NULL
and	NULL
13	NULL
%	NULL
for	NULL
NL4-3	NULL
and	NULL
respectively	NULL
,	NULL
at	NULL
day	NULL
10	NULL
post-infection	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
19	NULL
%	NULL
for	NULL
NLIxB-M	NULL
at	NULL
day	NULL
18	NULL
post-infection	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
IxBaS32/36A	NULL
did	NULL
not	NULL
affect	NULL
apoptosis	NULL
significantly	NULL
because	NULL
the	NULL
percentage	NULL
of	NULL
apoptotic	NULL
cells	NULL
among	NULL
those	NULL
infected	NULL
with	NULL
NL4-3	NULL
,	NULL
NLI	NULL
«	NULL
B-as	NULL
,	NULL
or	NULL
NLI	NULL
«	NULL
B-M	NULL
was	NULL
similar	NULL
.	NULL

NLIxB-M	NULL
Is	NULL
Stably	NULL
Attenuated	NULL
through	NULL
Cell	NULL
Passaging-Retroviruses	NULL
rapidly	NULL
delete	NULL
heterologous	NULL
genes	NULL
which	NULL
do	NULL
not	NULL
confer	NULL
benefits	NULL
for	NULL
replication	NULL
(	NULL
36-38	NULL
)	NULL
.	NULL

One	NULL
indication	NULL
of	NULL
such	NULL
a	NULL
loss	NULL
in	NULL
gained	NULL
function	NULL
would	NULL
be	NULL
a	NULL
change	NULL
in	NULL
the	NULL
kinetics	NULL
of	NULL
replication	NULL
in	NULL
later	NULL
(	NULL
compared	NULL
with	NULL
earlier	NULL
)	NULL
passages	NULL
of	NULL
viruses	NULL
.	NULL

In	NULL
examining	NULL
NLIxB-M	NULL
virus	NULL
after	NULL
prolonged	NULL
culturing	NULL
in	NULL
cells	NULL
,	NULL
we	NULL
noted	NULL
that	NULL
its	NULL
attenuated	NULL
phenotype	NULL
bred	NULL
true	NULL
despite	NULL
extended	NULL
re-passaging	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
A-C	NULL
)	NULL
.	NULL

No	NULL
changes	NULL
in	NULL
replication	NULL
phenotype	NULL
were	NULL
observed	NULL
with	NULL
up	NULL
to	NULL
180	NULL
days	NULL
(	NULL
9	NULL
passages	NULL
)	NULL
of	NULL
continuously	NULL
forced	NULL
propagation	NULL
in	NULL
ex	NULL
vivo	NULL
tissue	NULL
cultures	NULL
.	NULL

This	NULL
stability	NULL
of	NULL
IxB-a832/36A	NULL
contrasts	NULL
sharply	NULL
with	NULL
documented	NULL
findings	NULL
in	NULL
other	NULL
systems	NULL
where	NULL
rapid	NULL
deletion	NULL
of	NULL
gained	NULL
func-	NULL
TaBLE	NULL
I	NULL
Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
Jurkat	NULL
cells	NULL
infected	NULL
with	NULL
NL4-3	NULL
,	NULL
NLIxB-as	NULL
,	NULL
or	NULL
NLIxB-M	NULL
The	NULL
cells	NULL
were	NULL
analysed	NULL
by	NULL
flow	NULL
cytometry	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
p24	NULL
,	NULL
as	NULL
marker	NULL
of	NULL
viral	NULL
infection	NULL
,	NULL
and	NULL
for	NULL
binding	NULL
to	NULL
annexin	NULL
V	NULL
,	NULL
as	NULL
marker	NULL
of	NULL
apoptosis	NULL
.	NULL

Ten	NULL
thousand	NULL
cells	NULL
were	NULL
analysed	NULL
under	NULL
each	NULL
condition	NULL
.	NULL

Values	NULL
are	NULL
expressed	NULL
as	NULL
percentages	NULL
.	NULL

Cen	NULL
p24+	NULL
p24-C8	NULL
Annexin	NULL
V-	NULL
Annexin	NULL
V+	NULL
Annexin	NULL
V-	NULL
Annexin	NULL
V+	NULL
Day	NULL
10	NULL
post-infection	NULL
NL4-3	NULL
infected	NULL
T7	NULL
16	NULL
4	NULL
3	NULL
NLIxB-as	NULL
infected	NULL
68	NULL
10	NULL
18	NULL
4	NULL
NLIxB-M	NULL
infected	NULL
3	NULL
1	NULL
83	NULL
13	NULL
Uninfected	NULL
0.4	NULL
0.5	NULL
91	NULL
8.1	NULL
Day	NULL
18	NULL
post-infection	NULL
NL4-3	NULL
infected	NULL
8	NULL
69	NULL
1	NULL
22	NULL
NLIxB-as	NULL
infected	NULL
5	NULL
52	NULL
4	NULL
39	NULL
NLIxB-M	NULL
infected	NULL
19	NULL
4.5	NULL
63	NULL
18.5	NULL
Uninfected	NULL
1.4	NULL
1.6	NULL
84	NULL
13	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
HIV-1	NULL
Attenuation	NULL
by	NULL
Gain	NULL
of	NULL
IxB-	NULL
«	NULL
832/36A	NULL
Function	NULL
17571	NULL
A	NULL
JURKAT	NULL
2	NULL
0	NULL
25000	NULL
m	NULL
-*-	NULL
NLIxB-as	NULL
g	NULL
ike	NULL
48908	NULL
-*-	NULL
NLIxB-M	NULL
passage	NULL
1	NULL
‘	NULL
3	NULL
sso	NULL
coli	NULL
|	NULL
-	NULL
#	NULL
-	NULL
NLIxB-M	NULL
passage	NULL
6	NULL
é	NULL
1400084	NULL
|	NULL
160894	NULL
NLIxB-M	NULL
passage	NULL
9	NULL
o	NULL
g	NULL
s0007	NULL
/	NULL
s0004	NULL
-x-	NULL
mock	NULL
3	NULL
0+	NULL
0	NULL
-i	NULL
t-l-aPCMHC-i	NULL
10	NULL
20	NULL
30	NULL
40	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
Days	NULL
Days	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

NLIxB-M	NULL
virus	NULL
maintains	NULL
an	NULL
attenuated	NULL
phenotype	NULL
through	NULL
serial	NULL
B	NULL
OKT3-stimulated	NULL
PBMCs	NULL
passaging	NULL
.	NULL

Jurkat	NULL
(	NULL
panel	NULL
A	NULL
)	NULL
,	NULL
PBMCs	NULL
stimulated	NULL
with	NULL
mAb	NULL
OKT3	NULL
(	NULL
panel	NULL
B	NULL
)	NULL
,	NULL
aks	NULL
t	NULL
-4-	NULL
NLIxB-as	NULL
and	NULL
PBMCs	NULL
stimulated	NULL
with	NULL
PHA	NULL
(	NULL
panel	NULL
<	NULL
C	NULL
)	NULL
were	NULL
infected	NULL
with	NULL
NLIxB-as	NULL
,	NULL
E	NULL
so00	NULL
$	NULL
0004	NULL
-*-	NULL
NLIxB-M	NULL
passage	NULL
1	NULL
NLIxB-M	NULL
,	NULL
or	NULL
passaged	NULL
NLIxB-M	NULL
viruses	NULL
iG	NULL
,	NULL
and	NULL
measured	NULL
for	NULL
viral	NULL
production	NULL
as	NULL
de-	NULL
p	NULL
asso	NULL
40004	NULL
-e-	NULL
WNLIcB-M	NULL
passage	NULL
6	NULL
tailed	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

NLIxB-M	NULL
virus	NULL
was	NULL
ob-	NULL
€	NULL
-*-	NULL
NLIxB-M	NULL
passage	NULL
9	NULL
tained	NULL
through	NULL
serial	NULL
passages	NULL
in	NULL
Jurkat	NULL
&	NULL
2000	NULL
20004	NULL
--	NULL
mock	NULL
cells	NULL
by	NULL
collecting	NULL
the	NULL
RT	NULL
peak	NULL
of	NULL
viral	NULL
ic	NULL
production	NULL
at	NULL
each	NULL
passage	NULL
.	NULL

On	NULL
average	NULL
,	NULL
a	NULL
-	NULL
o+	NULL
each	NULL
passage	NULL
was	NULL
for	NULL
20	NULL
days	NULL
.	NULL

Panel	NULL
D	NULL
,	NULL
610	NULL
%	NULL
Cage	NULL
bs	NULL
ze	NULL
(	NULL
fs	NULL
``	NULL
C	NULL
PRT	NULL
YIT*A	NULL
RT-PCR	NULL
analysis	NULL
of	NULL
nef	NULL
and	NULL
integrase	NULL
re-	NULL
Days	NULL
Days	NULL
gions	NULL
of	NULL
NLIxB-M	NULL
virion	NULL
RNAs	NULL
.	NULL

The	NULL
wild-type	NULL
nef	NULL
product	NULL
(	NULL
802	NULL
bp	NULL
;	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
the	NULL
Anef	NULL
C	NULL
\	NULL
product	NULL
(	NULL
200	NULL
bp	NULL
;	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
the	NULL
I	NULL
«	NULL
B-a882¥/	NULL
PHA-stimulated	NULL
PBMCs	NULL
36A	NULL
product	NULL
(	NULL
1180	NULL
bp	NULL
;	NULL
lanes	NULL
4-7	NULL
)	NULL
,	NULL
and	NULL
the	NULL
sooo	NULL
integrase	NULL
product	NULL
(	NULL
575	NULL
bp	NULL
;	NULL
lanes	NULL
9-14	NULL
)	NULL
<	NULL
-*-	NULL
NLIxB-as	NULL
were	NULL
visualized	NULL
by	NULL
RT-PCR	NULL
of	NULL
viral	NULL
RNA	NULL
.	NULL

g	NULL
soo04	NULL
sooo	NULL
}	NULL
-*-	NULL
NLIxB-M	NULL
passage	NULL
1	NULL
Lane	NULL
1	NULL
,	NULL
100-bp	NULL
DNA	NULL
ladder	NULL
(	NULL
Life	NULL
Technol-	NULL
8	NULL
ogies	NULL
,	NULL
Inc.	NULL
)	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
9	NULL
,	NULL
amplification	NULL
of	NULL
g	NULL
4000	NULL
s0001	NULL
-	NULL
#	NULL
-	NULL
NLIxB-M	NULL
passage	NULL
6	NULL
NL4-3	NULL
virion	NULL
RNAs	NULL
from	NULL
298T	NULL
trans-	NULL
E	NULL
!	NULL

-*-	NULL
NLIxB-M	NULL
passage	NULL
9	NULL
fected	NULL
with	NULL
pNL4-8	NULL
.	NULL

Lanes	NULL
3	NULL
and	NULL
10	NULL
,	NULL
am-	NULL
&	NULL
-	NULL
2000-	NULL
20001	NULL
-x-	NULL
mock	NULL
plification	NULL
of	NULL
NLAnef	NULL
virion	NULL
RNAs	NULL
from	NULL
i	NULL
298T	NULL
transfected	NULL
with	NULL
pNLAnef	NULL
;	NULL
lanes	NULL
4	NULL
Fa	NULL
o	NULL
|	NULL
-Me	NULL
and	NULL
11	NULL
,	NULL
amplification	NULL
of	NULL
NLIxB-M	NULL
virion	NULL
000	NULL
s	NULL
)	NULL
de	NULL
rs	NULL
20	NULL
25	NULL
#	NULL
00	NULL
s0	NULL
900	NULL
G50	NULL
ro	NULL
ors	NULL
RNAs	NULL
from	NULL
298T	NULL
transfected	NULL
with	NULL
Days	NULL
Days	NULL
pNLIxB-M	NULL
;	NULL
Zanes	NULL
5	NULL
and	NULL
12	NULL
,	NULL
amplification	NULL
of	NULL
NLIKB-M	NULL
virion	NULL
RNAs	NULL
from	NULL
first	NULL
pas-	NULL
-	NULL
w.	NULL
i	NULL
-	NULL
w	NULL
:	NULL
@	NULL
sage	NULL
in	NULL
Jurkat	NULL
;	NULL
lanes	NULL
6	NULL
and	NULL
13	NULL
,	NULL
amplifica-	NULL
%	NULL
%	NULL
g	NULL
v	NULL
o	NULL
o	NULL
tion	NULL
of	NULL
NLIxB-M	NULL
virion	NULL
RNAs	NULL
from	NULL
sixth	NULL
D	NULL
2	NULL
2	NULL
a	NULL
2	NULL
2	NULL
2	NULL
passage	NULL
in	NULL
Jurkat	NULL
;	NULL
lanes	NULL
7	NULL
and	NULL
14	NULL
,	NULL
ampli-	NULL
§	NULL
§	NULL
E	NULL
3	NULL
a	NULL
g	NULL
fication	NULL
of	NULL
NLIKB-M	NULL
virion	NULL
RNAs	NULL
from	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
ninth	NULL
passage	NULL
in	NULL
Jurkat	NULL
;	NULL
lanes	NULL
8	NULL
and	NULL
15	NULL
,	NULL
Lo	NULL
4	NULL
I4	NULL
5	NULL
%	NULL
L0	NULL
I	NULL
%	NULL
I	NULL
RT	NULL
-negative	NULL
controls	NULL
.	NULL

=	NULL
§	NULL
9	NULL
92	NULL
9	NULL
9	NULL
®	NULL
#	NULL
o	NULL
a	NULL
a	NULL
a	NULL
%	NULL
4	NULL
1	NULL
1	NULL
1	NULL
i	NULL
%	NULL
4	NULL
k	NULL
%	NULL
®	NULL
i	NULL
#	NULL
os	NULL
2	NULL
J	NULL
3	NULL
g	NULL
#	NULL
a	NULL
g	NULL
g	NULL
J	NULL
g	NULL
2	NULL
2	NULL
Z	NULL
2	NULL
2	NULL
Z	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
Z	NULL
1180	NULL
bp	NULL
-	NULL
-	NULL
IkB-a	NULL
575	NULL
bp	NULL
-	NULL
-	NULL
integrase	NULL
10	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
tion	NULL
commenced	NULL
as	NULL
early	NULL
as	NULL
48	NULL
h	NULL
after	NULL
viral	NULL
passaging	NULL
(	NULL
36	NULL
)	NULL
.	NULL

To	NULL
verify	NULL
biochemically	NULL
that	NULL
this	NULL
phenotypic	NULL
stability	NULL
was	NULL
from	NULL
the	NULL
maintenance	NULL
of	NULL
I	NULL
«	NULL
B-	NULL
«	NULL
832/36A	NULL
in	NULL
nef	NULL
,	NULL
RT-PCR	NULL
analysis	NULL
of	NULL
virion	NULL
RNAs	NULL
was	NULL
performed	NULL
using	NULL
samples	NULL
isolated	NULL
after	NULL
various	NULL
times	NULL
of	NULL
culturing	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

Viral	NULL
RNAs	NULL
from	NULL
first	NULL
passage	NULL
(	NULL
20	NULL
days	NULL
in	NULL
culture	NULL
)	NULL
as	NULL
compared	NULL
with	NULL
sixth	NULL
(	NULL
120	NULL
days	NULL
in	NULL
culture	NULL
)	NULL
and	NULL
ninth	NULL
(	NULL
180	NULL
days	NULL
in	NULL
culture	NULL
)	NULL
passage	NULL
were	NULL
indistinguishable	NULL
,	NULL
providing	NULL
no	NULL
evidence	NULL
for	NULL
deletion	NULL
of	NULL
I	NULL
«	NULL
B-a832/836A	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
compare	NULL
lanes	NULL
5-7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
by	NULL
contrast	NULL
with	NULL
other	NULL
cDNAs	NULL
inserted	NULL
into	NULL
nef	NULL
(	NULL
36-38	NULL
)	NULL
in	NULL
the	NULL
setting	NULL
of	NULL
replicating	NULL
HIV-1/SIV	NULL
,	NULL
I	NULL
«	NULL
xB-	NULL
«	NULL
832/36A	NULL
is	NULL
unprecedently	NULL
stable	NULL
.	NULL

DISCUSSION	NULL
Various	NULL
approaches	NULL
have	NULL
been	NULL
proposed	NULL
for	NULL
generating	NULL
live-attenuated	NULL
HIV-1	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
findings	NULL
from	NULL
the	NULL
SIV	NULL
model	NULL
of	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
AIDS	NULL
,	NULL
loss-of-function	NULL
(	NULL
e.g	NULL
.	NULL

deletion	NULL
of	NULL
accessory	NULL
genes	NULL
such	NULL
as	NULL
nef	NULL
,	NULL
vpr	NULL
,	NULL
and	NULL
U3	NULL
)	NULL
has	NULL
been	NULL
forwarded	NULL
as	NULL
a	NULL
primary	NULL
approach	NULL
for	NULL
creating	NULL
enfeebled	NULL
,	NULL
but	NULL
replication-competent	NULL
,	NULL
HIV/SIV	NULL
(	NULL
1-6	NULL
)	NULL
.	NULL

Regrettably	NULL
,	NULL
recent	NULL
evidence	NULL
indicates	NULL
that	NULL
loss-of-function	NULL
alone	NULL
is	NULL
not	NULL
always	NULL
sufficient	NULL
(	NULL
and	NULL
is	NULL
perhaps	NULL
largely	NULL
insuffi-cient	NULL
)	NULL
to	NULL
prevent	NULL
virulence	NULL
(	NULL
7-11	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
one	NULL
is	NULL
faced	NULL
with	NULL
either	NULL
abandoning	NULL
live-attenuated	NULL
virus	NULL
as	NULL
a	NULL
potential	NULL
route	NULL
for	NULL
HIV-1	NULL
vaccine	NULL
or	NULL
devising	NULL
another	NULL
approach	NULL
which	NULL
is	NULL
mechanistically	NULL
distinct	NULL
from	NULL
and	NULL
could	NULL
be	NULL
used	NULL
additively	NULL
with	NULL
loss-of-function	NULL
in	NULL
attenuating	NULL
the	NULL
AIDS	NULL
virus	NULL
.	NULL

Attenuation	NULL
of	NULL
HIV-1	NULL
by	NULL
gain-of-function	NULL
was	NULL
first	NULL
broached	NULL
four	NULL
years	NULL
ago	NULL
(	NULL
40	NULL
)	NULL
.	NULL

However	NULL
,	NULL
an	NULL
issue	NULL
that	NULL
has	NULL
impeded	NULL
the	NULL
useful	NULL
application	NULL
of	NULL
gain-of-function	NULL
is	NULL
uncertainty	NULL
over	NULL
the	NULL
stability	NULL
of	NULL
functions	NULL
added	NULL
to	NULL
a	NULL
replicating	NULL
HIV-1	NULL
genome	NULL
.	NULL

To	NULL
date	NULL
,	NULL
all	NULL
exogenous	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
17572	NULL
open-reading	NULL
frames	NULL
,	NULL
such	NULL
as	NULL
thymidine	NULL
kinase	NULL
,	NULL
y-interferon	NULL
,	NULL
interleukin-2	NULL
(	NULL
36-38	NULL
)	NULL
,	NULL
when	NULL
artifactually	NULL
embedded	NULL
into	NULL
the	NULL
HIV-1/SIV	NULL
genome	NULL
have	NULL
been	NULL
unstable	NULL
to	NULL
prolonged	NULL
ex	NULL
vivo	NULL
passaging	NULL
,	NULL
suggesting	NULL
a	NULL
rule	NULL
of	NULL
rapid	NULL
deletion	NULL
of	NULL
gained	NULL
genes	NULL
upon	NULL
virus	NULL
replication	NULL
.	NULL

However	NULL
,	NULL
because	NULL
the	NULL
sampling	NULL
size	NULL
for	NULL
gained	NULL
functions	NULL
has	NULL
been	NULL
small	NULL
,	NULL
it	NULL
remains	NULL
unclear	NULL
whether	NULL
this	NULL
is	NULL
indeed	NULL
a	NULL
universal	NULL
rule	NULL
.	NULL

Our	NULL
findings	NULL
from	NULL
I	NULL
«	NULL
B-	NULL
«	NULL
832/36A	NULL
formally	NULL
challenge	NULL
the	NULL
rigidity	NULL
of	NULL
this	NULL
rule	NULL
.	NULL

An	NULL
ability	NULL
by	NULL
viruses	NULL
in	NULL
general	NULL
and	NULL
by	NULL
HIV-1	NULL
specifically	NULL
to	NULL
maintain	NULL
stably	NULL
gained	NULL
functions	NULL
should	NULL
not	NULL
be	NULL
inherently	NULL
sur-prising	NULL
.	NULL

For	NULL
example	NULL
,	NULL
piracy	NULL
of	NULL
large	NULL
numbers	NULL
of	NULL
cellular	NULL
genes	NULL
by	NULL
herpesviruses	NULL
has	NULL
been	NULL
well	NULL
documented	NULL
(	NULL
see	NULL
Ref	NULL
.	NULL

41	NULL
and	NULL
references	NULL
cited	NULL
therein	NULL
)	NULL
.	NULL

In	NULL
simple	NULL
animal	NULL
retroviruses	NULL
,	NULL
only	NULL
Gag	NULL
,	NULL
Pol	NULL
,	NULL
and	NULL
Env	NULL
open-reading	NULL
frames	NULL
are	NULL
required	NULL
for	NULL
virus	NULL
propagation	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
evolution	NULL
of	NULL
fat	NULL
,	NULL
rev	NULL
,	NULL
nef	NULL
,	NULL
upu	NULL
,	NULL
vif	NULL
,	NULL
and	NULL
upr	NULL
in	NULL
the	NULL
existing	NULL
HIV-1	NULL
genome	NULL
represents	NULL
likely	NULL
illustrations	NULL
of	NULL
how	NULL
this	NULL
virus	NULL
has	NULL
anciently	NULL
through	NULL
natural	NULL
means	NULL
acquired	NULL
and	NULL
continues	NULL
to	NULL
maintain	NULL
stably	NULL
added	NULL
reading	NULL
frames	NULL
.	NULL

Conceivably	NULL
,	NULL
IxB-a832/36A	NULL
has	NULL
certain	NULL
cellular	NULL
characteristics	NULL
that	NULL
benefit	NULL
the	NULL
virus-cell	NULL
interaction	NULL
during	NULL
HIV-1	NULL
replication	NULL
.	NULL

What	NULL
might	NULL
be	NULL
the	NULL
propitious	NULL
characteristics	NULL
specified	NULL
by	NULL
IkB-a832/36A	NULL
await	NULL
further	NULL
investigation	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
virus	NULL
transcription	NULL
by	NULL
IxB-	NULL
@	NULL
832/36A	NULL
allows	NULL
the	NULL
cell	NULL
to	NULL
survive	NULL
HIV-1	NULL
infection	NULL
,	NULL
while	NULL
cell	NULL
killing	NULL
occurs	NULL
in	NULL
the	NULL
case	NULL
of	NULL
recombinant	NULL
viruses	NULL
that	NULL
carry	NULL
exogenous	NULL
genes	NULL
which	NULL
do	NULL
not	NULL
confer	NULL
virus	NULL
attenuation	NULL
.	NULL

A	NULL
second	NULL
possible	NULL
explanation	NULL
for	NULL
the	NULL
insert	NULL
stability	NULL
in	NULL
NLIxB-M	NULL
is	NULL
that	NULL
IxB-a832/36A	NULL
could	NULL
provide	NULL
an	NULL
``	NULL
anti-mutator	NULL
``	NULL
effect	NULL
to	NULL
the	NULL
chimeric	NULL
HIV-1	NULL
genome	NULL
.	NULL

This	NULL
``	NULL
anti-mutator	NULL
``	NULL
effect	NULL
would	NULL
confer	NULL
a	NULL
relative	NULL
resistance	NULL
to	NULL
the	NULL
deletion	NULL
of	NULL
the	NULL
gained	NULL
function	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
IxB-a	NULL
«	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
correct	NULL
aberrant	NULL
DNA	NULL
synthesis	NULL
which	NULL
causes	NULL
genetic	NULL
instability	NULL
in	NULL
ataxia	NULL
telangectasia	NULL
cells	NULL
(	NULL
42	NULL
)	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
demonstrate	NULL
here	NULL
the	NULL
feasibility	NULL
of	NULL
a	NULL
gain-of-function	NULL
strategy	NULL
for	NULL
stably	NULL
attenuating	NULL
live	NULL
HIV-1	NULL
.	NULL

Specifi-cally	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
addition	NULL
of	NULL
IxB-a832/36A	NULL
to	NULL
an	NULL
HIV-1	NULL
genome	NULL
conferred	NULL
a	NULL
highly	NULL
attenuated	NULL
replication	NULL
phenotype	NULL
that	NULL
is	NULL
genetically	NULL
stable	NULL
for	NULL
a	NULL
minimum	NULL
of	NULL
180	NULL
days	NULL
of	NULL
growth	NULL
in	NULL
tissue	NULL
culture	NULL
.	NULL

Attenuated	NULL
replication	NULL
in	NULL
ex	NULL
vivo	NULL
tissue	NULL
culture	NULL
is	NULL
by	NULL
no	NULL
means	NULL
a	NULL
perfect	NULL
predictor	NULL
of	NULL
in	NULL
vivo	NULL
viral	NULL
robust-ness	NULL
;	NULL
however	NULL
,	NULL
the	NULL
unprecedented	NULL
observation	NULL
that	NULL
emerges	NULL
from	NULL
I	NULL
«	NULL
kB-	NULL
«	NULL
832/36A	NULL
is	NULL
its	NULL
durability	NULL
in	NULL
settings	NULL
where	NULL
other	NULL
artifactually	NULL
gained	NULL
open-reading	NULL
frames	NULL
(	NULL
36-38	NULL
)	NULL
have	NULL
failed	NULL
.	NULL

An	NULL
important	NULL
extension	NULL
to	NULL
the	NULL
experiments	NULL
here	NULL
would	NULL
be	NULL
to	NULL
explore	NULL
the	NULL
in	NULL
vivo	NULL
stability	NULL
of	NULL
IxB-	NULL
«	NULL
832/36A	NULL
in	NULL
chimeric	NULL
SIVs	NULL
propagated	NULL
in	NULL
macaques	NULL
.	NULL

However	NULL
,	NULL
the	NULL
fact	NULL
that	NULL
transcription	NULL
from	NULL
the	NULL
SIV	NULL
LTR	NULL
is	NULL
not	NULL
ruled	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
same	NULL
manner	NULL
as	NULL
that	NULL
from	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
43-45	NULL
)	NULL
undermines	NULL
the	NULL
feasibility	NULL
of	NULL
such	NULL
a	NULL
heterologous	NULL
in	NULL
vivo	NULL
test	NULL
for	NULL
IxB-	NULL
«	NULL
832/36A	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
further	NULL
studies	NULL
on	NULL
SIV	NULL
LTR-driven	NULL
transcription	NULL
are	NULL
warranted	NULL
to	NULL
identify	NULL
analogous	NULL
cellular	NULL
inhibitors	NULL
of	NULL
SIV	NULL
replication	NULL
.	NULL

That	NULL
not	NULL
withstanding	NULL
,	NULL
the	NULL
findings	NULL
from	NULL
I	NULL
«	NULL
B-a832/	NULL
36A	NULL
represent	NULL
a	NULL
first-step	NULL
proof	NULL
that	NULL
gain-of-function	NULL
could	NULL
be	NULL
a	NULL
stably	NULL
useful	NULL
approach	NULL
for	NULL
attenuation	NULL
.	NULL

This	NULL
first	NULL
step	NULL
should	NULL
spur	NULL
further	NULL
stepwise	NULL
exploration	NULL
for	NULL
other	NULL
useful	NULL
attenuating	NULL
markers	NULL
that	NULL
might	NULL
be	NULL
more	NULL
amenable	NULL
to	NULL
incremental	NULL
testing	NULL
in	NULL
nonhuman	NULL
primate	NULL
models	NULL
.	NULL

If	NULL
so	NULL
,	NULL
a	NULL
combination	NULL
approach	NULL
that	NULL
incorporates	NULL
gain-of-function	NULL
with	NULL
loss-of-function	NULL
could	NULL
possibly	NULL
contribute	NULL
toward	NULL
the	NULL
development	NULL
of	NULL
a	NULL
live-attenuated	NULL
HIV-1	NULL
vaccine	NULL
.	NULL

HIV-1	NULL
Attenuation	NULL
by	NULL
Gain	NULL
of	NULL
IxB-	NULL
«	NULL
832/36A	NULL
Function	NULL
REFERENCES	NULL
1	NULL
.	NULL

Daniel	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
Kirchhoff	NULL
,	NULL
F.	NULL
,	NULL
Czajak	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Sehgal	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
and	NULL
Desrosiers	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
258	NULL
,	NULL
1988-1941	NULL
2	NULL
.	NULL

Almond	NULL
,	NULL
N.	NULL
,	NULL
Kent	NULL
,	NULL
K.	NULL
,	NULL
Cranage	NULL
,	NULL
M.	NULL
,	NULL
Rud	NULL
,	NULL
E.	NULL
,	NULL
Clarke	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Stott	NULL
,	NULL
E.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Lancet	NULL
$	NULL
45	NULL
,	NULL
1842-1344	NULL
3	NULL
.	NULL

Wyand	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Manson	NULL
,	NULL
K.	NULL
H.	NULL
,	NULL
Garcia-Moll	NULL
,	NULL
M.	NULL
,	NULL
Montefiori	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Desrosiers	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

70	NULL
,	NULL
8724-8733	NULL
4	NULL
.	NULL

Beer	NULL
,	NULL
B.	NULL
,	NULL
Baier	NULL
,	NULL
M.	NULL
,	NULL
zur	NULL
Megede	NULL
,	NULL
J.	NULL
,	NULL
Norley	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Kurth	NULL
,	NULL
R.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

94	NULL
,	NULL
4062-4067	NULL
5	NULL
.	NULL

Shibata	NULL
,	NULL
R.	NULL
,	NULL
Siemon	NULL
,	NULL
C.	NULL
,	NULL
Czajak	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Desrosiers	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
and	NULL
Martin	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

71	NULL
,	NULL
8141-8148	NULL
6	NULL
.	NULL

Desrosiers	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Lifson	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Gibbs	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Czajak	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Howe	NULL
,	NULL
A.	NULL
Y.	NULL
,	NULL
Arthur	NULL
,	NULL
L.	NULL
O.	NULL
,	NULL
and	NULL
Johnson	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

72	NULL
,	NULL
1481-1487	NULL
7	NULL
.	NULL

Baba	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
Jeong	NULL
,	NULL
Y.	NULL
S.	NULL
,	NULL
Pennick	NULL
,	NULL
D.	NULL
,	NULL
Bronson	NULL
,	NULL
R.	NULL
,	NULL
Greene	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
and	NULL
Ruprecht	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
267	NULL
,	NULL
1820-1825	NULL
8	NULL
.	NULL

Wyand	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Manson	NULL
,	NULL
K.	NULL
H.	NULL
,	NULL
Lackner	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Desrosiers	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
Nat	NULL
.	NULL

Med	NULL
.	NULL

8	NULL
,	NULL
32-36	NULL
9	NULL
.	NULL

Cohen	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
24-25	NULL
10	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
Verhoef	NULL
,	NULL
K.	NULL
,	NULL
van	NULL
Wamel	NULL
,	NULL
J.	NULL
L.	NULL
B.	NULL
,	NULL
and	NULL
Back	NULL
,	NULL
N.	NULL
K.	NULL
T.	NULL
(	NULL
1999	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

78	NULL
,	NULL
1188-1145	NULL
11	NULL
.	NULL

Baba	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
Liska	NULL
,	NULL
V.	NULL
,	NULL
Khimani	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
Ray	NULL
,	NULL
N.	NULL
B.	NULL
,	NULL
Dailey	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Penninck	NULL
,	NULL
D.	NULL
,	NULL
Bronson	NULL
,	NULL
R.	NULL
,	NULL
Greene	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
McClure	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Martin	NULL
,	NULL
L.	NULL
N.	NULL
,	NULL
and	NULL
Ruprecht	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1999	NULL
)	NULL
Nat	NULL
.	NULL

Med	NULL
.	NULL

5	NULL
,	NULL
194-203	NULL
12	NULL
.	NULL

Coffin	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
267	NULL
,	NULL
483-489	NULL
13	NULL
.	NULL

Perelson	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Neumann	NULL
,	NULL
A.	NULL
U.	NULL
,	NULL
Markowitz	NULL
,	NULL
M.	NULL
,	NULL
Leonard	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Ho	NULL
,	NULL
D.	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
271	NULL
,	NULL
1582-1586	NULL
14	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
Nature	NULL
884	NULL
,	NULL
529-534	NULL
15	NULL
.	NULL

Finzi	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Siliciano	NULL
,	NULL
R.	NULL
F.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
98	NULL
,	NULL
665-671	NULL
16	NULL
.	NULL

Douek	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
McFarland	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Keiser	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Gage	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Massey	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Haynes	NULL
,	NULL
B.	NULL
F.	NULL
,	NULL
Polis	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Haase	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
Feinberg	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Sullivan	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Jamieson	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Zack	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Picker	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
and	NULL
Koup	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Nature	NULL
396	NULL
,	NULL
690-695	NULL
17	NULL
.	NULL

Marx	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Chen	NULL
,	NULL
Z	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Semin	NULL
.	NULL

Immunol	NULL
.	NULL

10	NULL
,	NULL
215-223	NULL
18	NULL
.	NULL

Littman	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
98	NULL
,	NULL
677-680	NULL
19	NULL
.	NULL

Rizzuto	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Wyatt	NULL
,	NULL
R.	NULL
,	NULL
Hernandez-Ramos	NULL
,	NULL
N.	NULL
,	NULL
Sun	NULL
,	NULL
Y.	NULL
,	NULL
Kwong	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Hendrickson	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
and	NULL
Sodroski	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Science	NULL
280	NULL
,	NULL
1949-1953	NULL
20	NULL
.	NULL

Roulston	NULL
,	NULL
A.	NULL
,	NULL
Lin	NULL
,	NULL
R.	NULL
,	NULL
Beauparlant	NULL
,	NULL
P.	NULL
,	NULL
Wainberg	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Hiscott	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Microbiol	NULL
.	NULL

Rev	NULL
.	NULL

59	NULL
,	NULL
481-505	NULL
21	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
Silverman	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Jeang	NULL
,	NULL
K-T.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
278-282	NULL
22	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
826	NULL
,	NULL
711-713	NULL
28	NULL
.	NULL

Mallardo	NULL
,	NULL
M.	NULL
,	NULL
Dragonetti	NULL
,	NULL
E.	NULL
,	NULL
Baldassarre	NULL
,	NULL
F.	NULL
,	NULL
Ambrosino	NULL
,	NULL
C.	NULL
,	NULL
Scala	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Quinto	NULL
,	NULL
I	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
20820-20827	NULL
24	NULL
.	NULL

Myers	NULL
,	NULL
G.	NULL
,	NULL
Korber	NULL
,	NULL
B.	NULL
,	NULL
Foley	NULL
,	NULL
B.	NULL
,	NULL
Jeang	NULL
,	NULL
K.	NULL
T.	NULL
,	NULL
Mellors	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
and	NULL
Wain-Hobson	NULL
,	NULL
S.	NULL
(	NULL
eds	NULL
)	NULL
(	NULL
1996	NULL
)	NULL
Human	NULL
Retroviruses	NULL
and	NULL
AIDS	NULL
1996	NULL
,	NULL
p.	NULL
1-3	NULL
,	NULL
Los	NULL
Alamos	NULL
National	NULL
Laboratory	NULL
,	NULL
Theoretical	NULL
Biology	NULL
and	NULL
Biophysics	NULL
Group	NULL
T-10	NULL
,	NULL
Los	NULL
Alamos	NULL
,	NULL
NM	NULL
25	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
May	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Kopp	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

16	NULL
,	NULL
225-260	NULL
26	NULL
.	NULL

Brown	NULL
,	NULL
K.	NULL
,	NULL
Gerstberger	NULL
,	NULL
S.	NULL
,	NULL
Carlson	NULL
,	NULL
L.	NULL
,	NULL
Franzoso	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Science	NULL
267	NULL
,	NULL
1485-1488	NULL
27	NULL
.	NULL

Brockman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Scherer	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
McKinsey	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Hall	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Qi	NULL
,	NULL
X.	NULL
,	NULL
Lee	NULL
,	NULL
W.	NULL
Y.	NULL
,	NULL
and	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
2809-2818	NULL
28	NULL
.	NULL

Adachi	NULL
,	NULL
A.	NULL
,	NULL
Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Koenig	NULL
,	NULL
S.	NULL
,	NULL
Folks	NULL
,	NULL
T.	NULL
,	NULL
Willey	NULL
,	NULL
R.	NULL
,	NULL
Rabson	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Martin	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

59	NULL
,	NULL
284-291	NULL
29	NULL
.	NULL

Connor	NULL
,	NULL
R.	NULL
I.	NULL
,	NULL
Chen	NULL
,	NULL
B.	NULL
K.	NULL
,	NULL
Choe	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Landau	NULL
,	NULL
N.	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Virology	NULL
206	NULL
,	NULL
935-944	NULL
30	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
782-784	NULL
31	NULL
.	NULL

Wang	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Mayo	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Jr.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
784-787	NULL
82	NULL
.	NULL

Van	NULL
Antwerp	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Martin	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Kafri	NULL
,	NULL
T.	NULL
,	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
and	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
787-789	NULL
33	NULL
.	NULL

Wright	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Jewett	NULL
,	NULL
A.	NULL
,	NULL
Mitsuyasu	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Bonavida	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

141	NULL
,	NULL
99-104	NULL
34	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
Kinter	NULL
,	NULL
A.	NULL
,	NULL
Justement	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Kehr	NULL
]	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Bressler	NULL
,	NULL
P.	NULL
,	NULL
Stanley	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Fauci	NULL
,	NULL
A	NULL
.	NULL

9	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
782-785	NULL
85	NULL
.	NULL

Martin	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Reutelingsperger	NULL
,	NULL
C.	NULL
P.	NULL
,	NULL
McGahon	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Rader	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
van	NULL
Schie	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
LaFace	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182	NULL
,	NULL
1545-1556	NULL
36	NULL
.	NULL

Smith	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Markham	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
and	NULL
Jeang	NULL
,	NULL
K.	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
7955-7960	NULL
37	NULL
.	NULL

Giavedoni	NULL
,	NULL
L.	NULL
D.	NULL
,	NULL
and	NULL
Yilma	NULL
,	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

70	NULL
,	NULL
2247-2251	NULL
38	NULL
.	NULL

Gundlach	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
Linhart	NULL
,	NULL
H.	NULL
,	NULL
Dittmer	NULL
,	NULL
U.	NULL
,	NULL
Sopper	NULL
,	NULL
S.	NULL
,	NULL
Reiprich	NULL
,	NULL
S.	NULL
,	NULL
Fuchs	NULL
,	NULL
D.	NULL
,	NULL
Fleckenstein	NULL
,	NULL
B.	NULL
,	NULL
Hunsmann	NULL
,	NULL
G.	NULL
,	NULL
Stahl-Hennig	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Uberla	NULL
,	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

71	NULL
,	NULL
2225-2282	NULL
39	NULL
.	NULL

Letvin	NULL
,	NULL
N.	NULL
L.	NULL
(	NULL
1998	NULL
)	NULL
Science	NULL
280	NULL
,	NULL
1875-1880	NULL
40	NULL
.	NULL

Kestler	NULL
,	NULL
H.	NULL
W.	NULL
,	NULL
and	NULL
Jeang	NULL
,	NULL
K.	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
270	NULL
,	NULL
1219	NULL
41	NULL
.	NULL

Nicholas	NULL
,	NULL
J.	NULL
,	NULL
Ruvolo	NULL
,	NULL
V.	NULL
,	NULL
Zong	NULL
,	NULL
J.	NULL
,	NULL
Ciufo	NULL
,	NULL
D.	NULL
,	NULL
Guo	NULL
,	NULL
H.	NULL
G.	NULL
,	NULL
Reitz	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
Hayward	NULL
,	NULL
G.	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

71	NULL
,	NULL
1963-1974	NULL
42	NULL
.	NULL

Jung	NULL
,	NULL
M.	NULL
,	NULL
Zhang	NULL
,	NULL
Y.	NULL
,	NULL
Lee	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Dritschilo	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Science	NULL
268	NULL
,	NULL
1619-1621	NULL
43	NULL
.	NULL

Ilyinskii	NULL
,	NULL
P.	NULL
O.	NULL
,	NULL
Simon	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Czajak	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Lackner	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Desrosiers	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

71	NULL
,	NULL
1880-1887	NULL
44	NULL
.	NULL

Zhang	NULL
,	NULL
J.	NULL
,	NULL
Novembre	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Rabson	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Virus	NULL
Res	NULL
.	NULL

49	NULL
,	NULL
205-218	NULL
45	NULL
.	NULL

Pohlmann	NULL
,	NULL
S.	NULL
,	NULL
Floss	NULL
,	NULL
S.	NULL
,	NULL
Iyinskii	NULL
,	NULL
P.	NULL
O.	NULL
,	NULL
Stamminger	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Kirchhoff	NULL
,	NULL
F.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

72	NULL
,	NULL
5589-5598	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Potent	NULL
and	NULL
Stable	NULL
Attenuation	NULL
of	NULL
Live-HIV-1	NULL
by	NULL
Gain	NULL
of	NULL
a	NULL
Proteolysis-resistant	NULL
Inhibitor	NULL
of	NULL
NF-	NULL
xB	NULL
(	NULL
IxB-	NULL
«	NULL
832/36A	NULL
)	NULL
and	NULL
the	NULL
Implications	NULL
for	NULL
Vaccine	NULL
Development	NULL
Ileana	NULL
Quinto	NULL
,	NULL
Massimo	NULL
Mallardo	NULL
,	NULL
Francesca	NULL
Baldassarre	NULL
,	NULL
Giuseppe	NULL
Scala	NULL
,	NULL
George	NULL
Englund	NULL
and	NULL
Kuan-Teh	NULL
Jeang	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1999	NULL
,	NULL
274:17567-17572.	NULL
doi	NULL
:	NULL
10.1074/jb0.274.25.17567	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
7567	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
44	NULL
references	NULL
,	NULL
30	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
7567	NULL
.	NULL

full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL

